Document:

Exhibit 10.15

 Exhibit 10.15 
 EXECUTION COPY 
 CONFIDENTIAL 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act
of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE RESEARCH COLLABORATION AGREEMENT 

THIS EXCLUSIVE RESEARCH COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of August 1, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and BIOLIFE CELL BANK, INC., a Delaware corporation having its principal
place of business at 11970 N. Central Expressway, Suite 280, Dallas, TX 75243 (“BioLife”). Intrexon and BioLife may be referred to herein individually as a “Party”, and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the
design and production of DNA vectors or their in vivo expression or the control of expression, as well as control over cell function; and 
 WHEREAS, BioLife now desires to become Intrexon’s exclusive research collaborator with respect to such technology for the purpose of developing the SMA
Therapeutics Program (as defined herein), and Intrexon is willing to appoint BioLife as a research collaborator in the Field (as defined herein) under the terms and conditions of this Agreement; and 

WHEREAS, BioLife desires the option to obtain exclusive commercial rights to Products (as
defined herein) developed through the SMA Therapeutics Program, and Intrexon is willing to provide BioLife with such an option under the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and
promises contained herein, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used in this Agreement, the following capitalized terms shall have the following meanings: 
 1.1 “Affiliate” means, with respect to a particular Party, any other person or entity that directly or indirectly controls, is controlled by, or is in common control with such
Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms “controlled by” and “under common control with”) means the ownership, directly or indirectly, of more than fifty
percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by
contract, or otherwise. Notwithstanding the foregoing, any person, corporation, partnership, or other entity that would be an Affiliate of a Party solely because it and such Party are under common control by Third Security or Randal J. Kirk shall
not be deemed to be an Affiliate of such Party solely by reason of such common control. 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.2 “Applicable Laws” has the meaning set forth in
Section 8.2(d)(xii). 
 1.3 “Authorizations” has the meaning set forth in Section 8.2(d)(xii).

 1.4 “BioLife Indemnitees” has the meaning set forth in Section 9.1. 

1.5 “BioLife Product” means any product in the Field that is created, produced, developed, or identified in whole
or in part, directly or indirectly, by or on behalf of BioLife during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials. 
 1.6 “BioLife Program Patent” has the meaning set forth in Section 6.2(b). 
 1.7 “BioLife Termination IP” means all Patents or other intellectual property that BioLife or any of its Affiliates Controls as of the Effective Date or during the Term that cover,
or is otherwise necessary or useful for, the development, manufacture or commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field. 
 1.8 “CC” has the meaning set forth in Section 2.2(b). 

1.9 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.10 “Claims” has the meaning set forth in Section 9.1. 

1.11 “CMCC” has the meaning set forth in Section 2.2(b). 

1.12 “Committees” has the meaning set forth in Section 2.2(a). 

1.13 “Commercialize” or “Commercialization” means any activities directed to marketing,
promoting, distributing, importing for sale, offering to sell and/or selling BioLife Products. 
 1.14
“Commercial Sale” means for a given product and country the sale for value of that product by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (and any
pricing or reimbursement approvals, if necessary) has been obtained for such product in such country. 
 1.15
“Complementary In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a). 
 1.16
“Confidential Information” means each Party’s confidential Information, inventions, non-public know-how or non-public data disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties and
shall include, without limitation, manufacturing, technical, marketing, financial, personnel and other business information and plans, whether in oral, written, graphic or electronic form. 

  
 2 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.17 “Control” means, with respect to Information, a Patent or
other intellectual property right, that a Party owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any
agreement or other arrangement with any Third Party. 
 1.18 “Cost of Goods Sold” means all
Manufacturing Costs that are directly and reasonably attributable to manufacturing of BioLife Product in accordance with US GAAP for commercial sale in the countries where such BioLife Product has been launched. 

1.19 “CRC” has the meaning set forth in Section 2.2(b). 

1.20 “Diligent Efforts” means, with respect to a Party’s obligation under this Agreement, the level of
efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each BioLife Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the
Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts
requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation. 

1.21 “Equity Agreements” has the meaning set forth in Section 5.1(c). 

1.22 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 

1.23 “Executive Officer” means : (i) the Chief Executive Officer of the applicable Party, or
(ii) another senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (a) a Committee dispute, provided that such appointed
officer is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (b) a dispute described in Section 11.1. 

1.24 “FDA” has the meaning set forth in Section 8.2(d)(xiii). 

1.25 “Field Infringement” has the meaning set forth in Section 6.3(b) 

1.26 “Field” means the production and use of adipose derived and other stem cells for the development and
commercialization of an autologous, genetically-modified, stem cell therapy to humans for the treatment of SMA, irrespective of whether such requires regulatory approval. 
 1.27 “Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good,
product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Sections 4.6 and 4.7 (as appropriate), Intrexon will bill for its internal direct costs incurred through the
use of annualized standard full-time 

  
 3 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good, product or service. Intrexon may, from time to time,
adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide BioLife with reasonable documentation indicating the
basis for any indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 
 1.28
“Information” means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications,
formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and
procedures, and patent and other legal information or descriptions. 
 1.29 “Infringement” has the
meaning set forth in Section 6.3(a). 
 1.30 “Initial Phase Research Plan” has the meaning set
forth in Section 2.1(b). 
 1.31 “Intrexon Channel Technology” means Intrexon’s current and
future technology directed towards the design, identification, culturing, and/or production of genetically modified autologous stem cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and
specifically including without limitation the following of Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) DNA and RNA MOD engineering, (3) protein engineering, (4) transcription control chemistry,
(5) genome engineering, and (6) cell system engineering. 
 1.32 “Intrexon Indemnitees” has
the meaning set forth in Section 9.2. 
 1.33 “Intrexon IP” means the Intrexon Patents and Intrexon
Know-How. 
 1.34 “Intrexon Know-How” means all Information (other than Intrexon Patents) that
(a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is reasonably required or useful for BioLife to conduct the SMA Therapeutics Program. For the avoidance of doubt, the Intrexon Know-How shall include any
Information (other than Intrexon Patents) in the Channel-Related Program IP. 
 1.35 “Intrexon
Materials” means the genetic code and associated amino acids and gene constructs used alone or in combination and such other proprietary reagents including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies,
and ligand-related chemistry, in each case that are reasonably required or provided to BioLife to conduct the SMA Therapeutics Program. 
 1.36 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or during the Term; and (b) are reasonably required or useful for
BioLife to conduct the SMA Therapeutics Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

  
 4 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.37 “Intrexon Trademarks” means those trademarks related to the
Intrexon Channel Technology that are established from time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.38 “Inventions” has the meaning set forth in Section 6.1(b). 
 1.39 “IPC” has the meaning set forth in Section 2.2(b). 
 1.40 “JSC” has the meaning set forth in Section 2.2(b). 
 1.41 “SMA” means spinal muscular atrophy, the autosomal recessive disease caused by a genetic defect in the SMN1gene that results in death of neuronal cells in the anterior horn of
the spinal cord and subsequent system-wide muscle wasting. 
 1.42 “SMA Therapeutics Program” has the
meaning set forth in Section 2.1. 
 1.43 “Losses” has the meaning set forth in Section 9.1.

 1.44 “Manufacturing Costs” means, with respect to BioLife Products, the full-time equivalent costs
(under a reasonable accounting mechanism to be agreed upon by the Parties) and out-of-pocket costs of a Party or any of its Affiliates incurred in manufacturing such BioLife Products, including costs and expenses incurred in connection with
(1) the development or validation of any manufacturing process, formulations or delivery systems, or improvements to the foregoing; (2) manufacturing scale-up; (3) in-process testing, stability testing and release testing;
(4) quality assurance/quality control development; (5) internal and Third Party costs and expenses incurred in connection with qualification and validation of Third Party contract manufacturers, including scale up, process and equipment
validation, and initial manufacturing licenses, approvals and inspections; (6) packaging development and final packaging and labeling; (7) shipping configurations and shipping studies; and (8) overseeing the conduct of any of the
foregoing. “Manufacturing Costs” shall further include: (a) to the extent that any such BioLife Product is manufactured by a Third Party manufacturer, the out-of-pocket costs incurred by such Party or any of its Affiliates to the
Third Party for the manufacture and supply (including packaging and labeling) thereof, and any reasonable out-of-pocket costs and direct labor costs incurred by such Party or any of its Affiliates in managing or overseeing the Third Party
relationship determined in accordance with the books and records of such Party or its Affiliates maintained in accordance with US GAAP; and (b) to the extent that any such BioLife Product is manufactured by such Party or any of its Affiliates,
direct material and direct labor costs attributable to such BioLife Product, as well as reasonably allocable overhead expenses, determined in accordance with the books and records of such Party or its Affiliates maintained in accordance with US
GAAP. 
 1.45 “Net Sales” means, with respect to any BioLife Product, the net sales of such BioLife
Product by BioLife or an Affiliate of BioLife (including without limitation net sales of BioLife Product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee), as determined in accordance with US GAAP as
the gross amount of sales of BioLife Product less the usual and customary discounts as determined in accordance with US 

  
 5 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
GAAP. In the case of any sale for value, such as barter or counter-trade other than in an arm’s length transaction exclusively for cash, Net Sales shall be deemed to be the net sales at
which substantially similar quantities of the product are sold for cash in an arm’s length transaction in the relevant country. If BioLife Product is sold to any third party together with other products or services, the price of such product,
solely for purposes of the calculation of Net Sales, shall be deemed to be no less than the price at which such product would be sold in a similar transaction to a third party not also purchasing the other products or services. 

1.46 “Option Period” means the longer of (i) the period of time from the Effective Date to the one-year
anniversary of the Effective Date, or (ii) upon the written mutual agreement of the Parties to extend the Option Period, the period of time from the Effective Date to the fifteen-month anniversary of the Effective Date. 

1.47 “Patents” means (a) all patents and patent applications (including provisional applications),
(b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the
foregoing, and (c) any foreign or international equivalents of any of the foregoing. 
 1.48 “Product
Profit” means Net Sales less Cost of Goods Sold. 
 1.49 “Product-Specific Program Patent”
means any issued Intrexon Patent where all the claims are directed to Inventions that relate solely and specifically to BioLife Products. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a
Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to
Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or
(b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 
 1.50 “Product Sublicense” has the meaning set forth in Section 3.2(c). 
 1.51 “Product Sublicensee” has the meaning set forth in Section 3.2(c). 
 1.52 “Proposed Terms” has the meaning set forth in Section 11.2. 
 1.53 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 
 1.54 “Recovery” has the meaning set forth in Section 6.3(f). 
 1.55 “Retained Product” has the meaning set forth in Section 10.4(a). 
 1.56 “Reverted Product” has the meaning set forth in Section 10.4(c). 

  
 6 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.57 “SEC” means the United States Securities and Exchange
Commission. 
 1.58 “Stock Issuance Agreement” has the meaning set forth in Section 5.1(b).

 1.59 “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash
consideration, regardless of whether in the form of upfront payments, milestones, or royalties, actually received by BioLife or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to
develop or commercialize BioLife Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration
for a grant of equity of BioLife to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); (c) any amounts, up to a maximum of ten percent
(10%) of net sales per BioLife Product, paid by BioLife to a Third Party for the right to operate under or utilize Third Party owned intellectual property that is used to make or use a BioLife Product underlying the Sublicensing Revenue, and
(d) amounts received from sublicensees in respect of any BioLife Product sales that are included in Net Sales. 

1.60 “Superior Therapy” means a therapy in the Field that, based on the data then available,
(a) demonstrably appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by BioLife or others) at such time for the indication and
(ii) those therapies that are being actively developed by BioLife for such indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has intellectual property protection and a
regulatory approval pathway that, in each case, would not present a significant barrier to commercial development. 

1.61 “Supplemental In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a). 

1.62 “Support Memorandum” has the meaning set forth in Section 11.2. 

1.63 “Technology Access Fee” has the meaning set forth in Section 5.1. 

1.64 “Term” has the meaning set forth in Section 10.1. 

1.65 “Territory” means the entire world. 

1.66 “Third Party” means any individual or entity other than the Parties or their respective Affiliates.

 1.67 “Third Party IP” has the meaning set forth in Section 3.8(a). 

1.68 “Third Security” means Third Security, LLC. 

  
 7 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.69 “US GAAP” means generally accepted accounting principles in
the United States of America. 
 ARTICLE 2 
 SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 
 2.1 Structure. 
 (a) Generally. The general purpose of
the research collaboration described in this Agreement will be to use the Intrexon Channel Technology to research, develop and, subject to exercise by BioLife of the option under Section 5.1 as described herein, commercialize products for use
in the Field (collectively, the “SMA Therapeutics Program”). 
 (b) Research Phase Activities.
The Parties will, with Diligent Efforts after the Effective Date, meet and confer to establish and agree upon a research plan that details certain research activities (and associated goals, timelines, and projected costs for those research
activities) that will be conducted by the Parties during the Option Period in support of the SMA Therapeutics Program (the “Initial Phase Research Plan”). The Initial Phase Research Plan will be agreed upon as promptly as
practicable following the Effective Date, and may thereafter be amended or revised by mutual agreement of the Parties. BioLife agrees that, upon being invoiced by Intrexon, BioLife will reimburse Intrexon, in cash and within thirty (30) days of
invoice date, for Intrexon’s Fully Loaded Costs in connection with Intrexon’s performance under the Initial Phase Research Plan and Intrexon’s efforts following execution of the Agreement towards generation of the Initial Phase
Research Plan. Intrexon will report to BioLife regarding the status of its activities under the Initial Phase Research Plan, including results and associated data for any activities conducted thereunder. 

(c) Post-Option Channel Collaboration. In the event BioLife exercises the option under Section 5.1 during the Option
Period, the present Agreement will immediately convert into an exclusive channel collaboration as described herein and BioLife will become Intrexon’s exclusive channel collaborator in the Field. As provided below, the JSC will be constituted
following the successful exercise of BioLife’s option, and the JSC shall thereafter establish, monitor, and govern projects for the SMA Therapeutics Program as described below. Either Party may propose potential projects in the Field for review
and consideration by the JSC. 
 2.2 Committees. 

(a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to oversee
the SMA Therapeutics Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the
obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 

  
 8 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) Formation and Purpose. In the event BioLife exercises the option under
Section 5.1 during the Option Period, the Parties shall promptly thereafter confer and then create the Committees listed in the chart below, each of which shall have the purpose indicated in the chart. To the extent that after conferring both
Parties agree that a given Committee need not be created until a later date, the Parties may agree to defer the creation of the Committee until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point
the Parties will thereafter promptly create the so-deferred Committee and schedule a meeting of such Committee within one (1) month. 
  

			
	 Committee
	  	 Purpose

		
	Joint Steering Committee (“JSC”)	  	Establish projects for the SMA Therapeutics Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and
plans.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the SMA Therapeutics Program.
		
	Clinical/Regulatory Committee (“CRC”)	  	Review and approve all research and development plans, clinical projects and publications, and regulatory filings and correspondence under the SMA Therapeutics Program; review and
approve itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for commercialization activities under the SMA Therapeutics Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate intellectual property issues in connection with the SMA Therapeutics Program; review and approve itemized budgets with respect to the foregoing.

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed four
(4) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the

  
 9 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
representatives must all be employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other Committee up to one (1) representative who
is not an employee if : (i) such non-employee representative agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party
consents to the designation of such non-employee representative, which consent shall not be unreasonably withheld. Each representative as qualified above may serve on more than one Committee as appropriate in view of the individual’s expertise.
Each Party may replace its Committee representatives at any time upon written notice to the other Party. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which
representative to the Committee will act as chairperson shall alternate between the Parties, with BioLife selecting the chairperson first for the JSC, CRC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of
each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 

(b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings
be held less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to
reactivate the so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of
telecommunication (telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with BioLife selecting the first meeting
location for each Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee
excepting that an Intrexon employee or agent serving on a Committee shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing manufacturing or support
services as set forth in Sections 4.6 and 4.7 below. 
 (c) Meeting Agendas. Each Party will disclose to the other
proposed agenda items along with appropriate information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of
time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee
meeting. 
 (d) Limitations of Committee Powers. Each Committee shall have only such powers as are specifically
delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any
power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. 

  
 10 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 2.4 Committee Decision-Making. If a Committee is unable to reach unanimous
consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the
Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such
dispute to the Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such officers, then the Executive Officer of the Party specified in the applicable
subsection below shall have the authority to finally resolve such dispute acting in good faith. 
 (a) Casting Vote at
JSC. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then the Executive Officer of BioLife shall have the authority to finally resolve such dispute. 

(b) Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the
case of any disputes relating to the Intrexon Materials, the manufacture of a BioLife Product active pharmaceutical ingredient, or the manufacturing of other components of BioLife Products contracted for or manufactured by Intrexon, the Executive
Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of BioLife shall have the authority to finally resolve such dispute. 

(c) Casting Vote at CRC. If a dispute at the CRC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of BioLife shall have the authority to finally resolve such dispute. 
 (d) Casting Vote at CC. If a
dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of BioLife shall have the authority to finally resolve such dispute. 
 (e) Casting Vote at IPC. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such
dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11).

 (f) Other Committees. If any additional Committee other than those set forth in Section 2.2(b) is formed,
then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 

  
 11 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (g) Restrictions. Neither Party shall exercise its right to finally
resolve a dispute at a Committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party
under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement;
(v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. 

ARTICLE 3 

LICENSE GRANTS 
 3.1 Licenses to BioLife. 
 (a) During the Option Period, and
subject to the terms and conditions of this Agreement, Intrexon hereby grants to BioLife a limited license under the Intrexon IP to research, develop, and use BioLife Products in the Field in the Territory. Such license shall be exclusive in the
Field, and shall be otherwise non-exclusive. 
 (b) Subject to the exercise by BioLife of the option under
Section 5.1 and the terms and conditions of this Agreement, Intrexon hereby grants to BioLife a license under the Intrexon IP to research, develop, use, import, export, make, have made, sell, and offer for sale BioLife Products in the Field in
the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any clinical development, selling, offering for sale or other Commercialization of BioLife Products in the Field, and shall be otherwise non-exclusive. 

(c) Subject to the exercise by BioLife of the option under Section 5.1 and the terms and conditions of this Agreement,
Intrexon hereby grants to BioLife a non-exclusive, royalty-free license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of BioLife Products, in the promotional materials, packaging, and labeling for
BioLife Products, as provided under and in accordance with Section 4.9. 
 3.2 Sublicensing. Except as
provided below, BioLife shall not sublicense the rights granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or
Commercialize BioLife Products or use or display the Intrexon Trademarks, in each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, upon
successful execution by BioLife of its option under Section 5.1 BioLife (and its Product Sublicensees only to the extent explicitly set forth in Section 3.2(a) below) shall have a limited right to sublicense under the circumstances
described in Sections 3.2(a) through 3.2(c) below. 
 (a) BioLife may transfer, to the extent reasonably necessary,
Intrexon Materials that are or express active pharmaceutical ingredients to a Third Party contractor 

  
 12 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
performing fill/finish responsibilities for BioLife Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If BioLife
transfers any Intrexon Materials under this Section 3.2(a), BioLife will take commercially reasonable steps to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of
this Agreement are not violated by any such Third Party contractor. A Product Sublicensee of BioLife may transfer, to the extent reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, Intrexon
Materials that are or express active pharmaceutical ingredients to a Third Party contractor performing fill/finish responsibilities for BioLife Products duly sublicensed to that Product Sublicensee, and may in connection therewith grant limited
sublicenses to the extent necessary to enable such Third Party to perform such activities. BioLife will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such Product
Sublicensee, after obtaining Intrexon’s consent, will take commercially reasonable steps to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are
not violated by any such Third Party contractor. 
 (b) BioLife may, with Intrexon’s written consent, sublicense the
rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate the right to research, develop, use, or Commercialize BioLife Products or use or display the Intrexon Trademarks. In the
event that Intrexon consents to any such grant or transfer to an Affiliate, BioLife shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this
Agreement in connection with such performance (as though such Affiliate were BioLife), including any payment obligations owed to Intrexon hereunder. 
 (c) BioLife may, with Intrexon’s written consent, grant a sublicense of the rights granted under Section 3.1 to a Third Party licensee of any BioLife Product (a “Product
Sublicensee”) to the extent necessary to permit such Third Party to research, develop, use, import, export, make, sell, and offer for sale that BioLife Product (a “Product Sublicense”), provided, that (i) such Product
Sublicense is expressly limited to the appropriate BioLife Product, (ii) does not grant the Product Sublicensee any rights to Intrexon IP other than that incorporated into the BioLife Product at the time of the Product Sublicense,
(iii) does not purport to relieve BioLife of any of its obligations under this Agreement, (iv) the Product Sublicensee agrees in writing, in a document in form reasonably acceptable to Intrexon and to which Intrexon is an express third
party beneficiary, to abide by the following provisions of this Agreement: Sections 3.1, 3.2(a), 3.3-3.6, 3.8, 3.10, 3.11, and 4.6 and Articles 6, 7, and 10), and (v) the Product Sublicense is presented in full to the JSC by BioLife before
execution by BioLife and the prospective Product Sublicensee and as soon as is reasonably practical during negotiations thereof for the purpose of allowing the JSC to review and comment upon the terms and scope of the Product Sublicense agreement.

 3.3 Limitation on Sublicensees. None of the enforcement rights under the Intrexon Patents that are granted to
BioLife pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole discretion. 

  
 13 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.4 No Non-Permitted Use. BioLife hereby covenants that it shall not, nor
shall it permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement.

 3.5 Exclusivity. Intrexon and BioLife mutually agree that, under the collaboration established by this
Agreement, it is intended that the Parties will be exclusive to each other in the Field. To this end, during the Term neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials available to any Third Party
for the purpose of developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the research, development or
Commercialization of any product for purpose of sale in the Field, outside of the SMA Therapeutics Program. Further, other than BioLife’s activities within the SMA Therapeutics Program, during the Term neither BioLife nor its Affiliates shall
pursue (either by itself or with a Third Party or Affiliate) the research, development or Commercialization of any product for purpose of sale in the Field. 
 3.6 Off Label Use. For purpose of clarity, (a) following the Commercial Sale of a BioLife Product, the use by direct or indirect purchasers or other users of BioLife Products outside
the Field (i.e. “off label use”) shall not constitute a breach by BioLife of the terms of Section 3.3, 3.4 or 3.5, provided that neither BioLife nor its Affiliate (nor any Third Party under contract with either of them) marketed or
promoted BioLife Products for such off-label use; and (b) following the Commercial Sale of a product by Intrexon, an Intrexon Affiliate, or a Third Party sublicensee, collaborator, or partner of Intrexon, the use by direct or indirect
purchasers or other users of such products in the Field (i.e. “off label use”) shall not constitute a breach by Intrexon of the terms of Section 3.5, provided that neither Intrexon nor its Affiliate (nor any Third Party under contract
with either of them) marketed or promoted such products for such off-label use. 
 3.7 No Prohibition on Intrexon.
Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the
right to do the same. Without limiting the generality of the foregoing, BioLife acknowledges that Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any active
pharmaceutical ingredient used in a BioLife Product), and Intrexon IP available to Third Party channel partners or collaborators for use in fields outside the Field. 
 3.8 Rights to Clinical and Regulatory Data. BioLife shall own and control all clinical data and regulatory filings relating to Commercialization of BioLife Products during the Term. BioLife
shall provide at Intrexon’s request full copies of all clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities that relate 

  
 14 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
specifically and solely to BioLife Products. To the extent that there exist any clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities
owned by BioLife or a Product Sublicensee that relate both to BioLife Products and other products produced by BioLife or a Product Sublicensee outside the Field, BioLife shall provide (or require that the Product Sublicensee provide) to Intrexon
upon Intrexon’s request copies of the portions of such data, reports, filings, and communications that relate to BioLife Products. Intrexon shall be permitted, directly or in conjunction with or through partners or other channel collaborators,
to reference this data, reports, filings, and communications relating to BioLife Products in regulatory filings made to obtain regulatory approval for products indicated for use in fields outside the Field. Intrexon shall have the right to use any
such information in developing and Commercializing products outside the Field and to license any Third Parties to do so. 

3.9 Third Party Licenses. 
 (a) [*****] shall obtain [*****] any licenses from Third Parties that are required in order to practice the Intrexon Channel Technology in the Field where the licensed intellectual property is
directed towards the manufacture of gene constructs, vectors, transgenes, or methods for altering or controlling genetic expression (but excluding intellectual property directed to any stem cells or specific methods of treating humans, collecting or
processing autologous stem cells, or delivering cells to humans for purposes of therapy) (“Supplemental In-Licensed Third Party IP”). Other than with respect to Supplemental In-Licensed Third Party IP, [*****] shall be solely
responsible for obtaining [*****] any licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import BioLife Products (“Complementary In-Licensed
Third Party IP”). Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “Third Party IP”. 

(b) In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP or
Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such Third Party IP and its applicability to the BioLife Products and to the Field. As provided above in Section 3.9(a), [*****]
shall have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time,
provided that [*****] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against [*****] or its
Affiliates and, after written notice to [*****] of such action, [*****] fails to obtain a license to such Supplemental In-Licensed Third Party IP within ninety (90) days after such notice. Following the IPC’s discussion of any
Complementary In-Licensed Third Party IP, subject to Section 3.8(c), [*****] shall have the right to pursue a license under Complementary In-Licensed Third Party IP [*****]. For the avoidance of doubt, [*****] may at any time obtain a license
under Complementary In-Licensed Third Party IP outside the Field [*****] provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with
[*****]. 

  
 15 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) [*****] shall provide the proposed terms of any license under Complementary
In-Licensed Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments thereto in good faith.
To the extent that [*****] obtains a license under Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license agreement for such Supplemental In-Licensed Third Party IP to the IPC. If [*****] acquires
rights under any Third Party IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be exclusive. Any Party that is pursuing a license to any Third
Party IP with respect to the Field under this Section 3.9 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity, (i) any costs incurred by [*****] in obtaining and
maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP (and, to the limited
extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [*****]. 
 (d) For
any Third Party license under which BioLife or its Affiliates obtain a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture, and/or Commercialization of BioLife Products, BioLife
shall use commercially reasonable efforts to ensure that BioLife will have the ability, pursuant to Section 10.4(h), to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in
Section 10.4(h)). 
 (e) The licenses granted to BioLife under Section 3.1 may include sublicenses under
Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set forth in
Section 3.9(c), provided that Intrexon shall either provide unredacted copies of such upstream license agreements to BioLife or shall disclose in writing to BioLife all of such terms and conditions that are applicable to BioLife.
BioLife shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to BioLife as provided in the preceding sentence. 

(f) If either Party receives notice from a Third Party concerning activities of a Party taken in conjunction with performance of
obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving Party shall inform the other party
thereof within five (5) business days. 
 3.10 Licenses to Intrexon. Subject to the terms and conditions of
this Agreement, BioLife hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by BioLife or its Affiliates, solely to the extent necessary for
Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any of Intrexon’s permitted subcontractors. 

  
 16 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.11 Restrictions Relating to Intrexon Materials. BioLife and its
permitted sublicensees shall use the Intrexon Materials solely for purposes of the SMA Therapeutics Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising
Intrexon’s vector assembly technology, BioLife shall not, and shall ensure that BioLife personnel and permitted sublicensees do not (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party;
(b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or sequence such
Intrexon Materials. 
 ARTICLE 4 
 OTHER RIGHTS AND OBLIGATIONS 
 4.1 Development and Commercialization. Subject to Sections 4.6 and 4.7, BioLife shall be solely responsible for the performance of the SMA Therapeutics Program and the development and, upon
successful execution by BioLife of its option under Section 5.1, Commercialization of BioLife Products in the Field. BioLife shall be responsible for all costs incurred in connection with the SMA Therapeutics Program except that Intrexon shall
be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable
portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing BioLife Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized
that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for
clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a BioLife Product (which research costs shall be reimbursed by BioLife); (c) [*****]; and (d) costs of filing, prosecution
and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and commercialization of BioLife Products
undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or BioLife (with Intrexon’s consent).

 4.2 Transfer of Technology and Information. The JSC shall develop a plan and protocol for each project and
timing for the transfer of relevant data and Intrexon Materials. 
 4.3 Information and Reporting. BioLife will
keep Intrexon informed about BioLife’s efforts to develop and, upon successful execution by BioLife of its option under Section 5.1, commercialize BioLife Products, including reasonable and accurate summaries of

  
 17 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
BioLife’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing
plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or commercialization of the BioLife Products, including initiation
or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical safety event, receipt of Regulatory Approval, or commercial
launch. As set forth in Section 3.8 above, BioLife shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by BioLife as
soon as practical after they become available. Intrexon will keep BioLife informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for BioLife Products (and Intrexon Materials relevant thereto) and
otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the SMA Therapeutics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise
provided herein, such disclosures by BioLife and Intrexon will be made in the course of JSC meetings at least once every six (6) months while BioLife Products are being developed or commercialized anywhere in the world, and shall be reflected
in the minutes of such meetings. 
 4.4 Regulatory Matters. At all times after the Effective Date, BioLife shall
own and maintain, at its own cost, all regulatory filings and regulatory approvals for BioLife Products that BioLife is developing or, upon successful execution by BioLife of its option under Section 5.1, Commercializing pursuant to this
Agreement. As such, BioLife shall be responsible for reporting all adverse events related to such BioLife Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such
countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon Materials outside of the Field, Intrexon may request that BioLife and Intrexon establish and execute a separate safety data
exchange agreement, which agreement will address and govern the timely exchange of safety information generated by BioLife, Intrexon, and relevant third parties with respect to specific Intrexon Materials. The decision to list or not list Patents in
any regulatory filing for a BioLife Product (for example, as required by 21 C.F.R. § 314.53(b)), add or delete a Patent from a regulatory filing, or to otherwise identify a Patent to a third party in compliance with laws or regulations relating
to regulatory approvals (for example, in compliance with 42 U.S.C. § 262(a)(1)(A)(k) et seq.) shall be determined by Intrexon, after consultation with BioLife, except with respect to Product Specific Program Patents, which will be mutually
determined by the Parties. 
 4.5 Diligence. 

(a) BioLife shall use, and shall require its sublicensees to use, Diligent Efforts to develop and, upon successful execution by
BioLife of its option under Section 5.1, commercialize BioLife Products. 
 (b) Without limiting the generality of
the foregoing, Intrexon may, from time to time, notify BioLife that it believes it has identified a Superior Therapy, and in such case 

  
 18 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Intrexon shall provide to BioLife its then-available information about such therapy and reasonable written support for its conclusion that the therapy constitutes a Superior Therapy. BioLife
shall have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification, BioLife shall prepare and deliver to the research committee (if prior to execution by BioLife of its
option under Section 5.1) or JSC, as applicable, for review and approval a development plan detailing how BioLife will pursue the Superior Therapy (including a proposed budget); (ii) BioLife shall revise the development plan as directed by
the committee; and (iii) following approval of the development plan by the committee, BioLife shall use Diligent Efforts to pursue the development of the Superior Therapy under the SMA Therapeutics Program in accordance with such development
plan. If BioLife fails to comply with the foregoing obligations, or if BioLife unreasonably exercises its casting vote at the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more
than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the Superior Therapy, then Intrexon shall
have the termination right set forth in Section 10.2(c) (subject to the limitation set forth therein). For clarity, any dispute arising under this 4.5, including any dispute as to whether a proposed project constitutes a Superior Therapy (as
with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11. 
 (c)
The activities of BioLife’s Affiliates and any permitted sublicensees shall be attributed to BioLife for the purposes of evaluating BioLife’s fulfillment of the obligations set forth in this Section 4.5. 

4.6 Manufacturing. Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform
any manufacturing activities in connection with the SMA Therapeutics Program that relate to the Intrexon Materials, the manufacture of bulk drug product, the manufacturing of bulk quantities of other components of BioLife Products, or any earlier
steps in the manufacturing process for BioLife Products. To the extent that Intrexon so elects, Intrexon may request that BioLife and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and
govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be
performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials,
bulk drug product or bulk quantities of other components of BioLife Products, then Intrexon shall provide to BioLife or a contract manufacturer selected by BioLife and approved by Intrexon all Information Controlled by Intrexon that is related to
the manufacturing of such Intrexon Materials, bulk drug product or bulk qualities of other components of BioLife Products, for use in the Field and is reasonably necessary to enable BioLife or such contract manufacturer (as appropriate) for the sole
purpose of manufacturing such Intrexon Materials, bulk drug product or bulk quantities of other components of BioLife Products, in each case as manufactured by Intrexon. The costs and expenses incurred by Intrexon in carrying out such transfer shall
be borne by Intrexon. Any manufacturing Information transferred hereunder to BioLife or its contract manufacturer shall 

  
 19 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
not be further transferred to any Third Party, including any Product Sublicensee, or any BioLife Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall
not unreasonably withhold such consent if necessary to permit BioLife to switch manufacturers. 
 4.7 Support
Services. From time to time, on an ongoing basis, BioLife shall request, or Intrexon may propose, that Intrexon perform certain support services with respect to the SMA Therapeutics Program. To the extent that the Parties mutually agree that
Intrexon should perform such services, the Parties shall negotiate in good faith the terms under which services would be performed, it being understood that Intrexon would be compensated for such services by cash payments equal to Intrexon’s
Fully Loaded Cost in connection with such services. 
 4.8 Compliance with Law. Each Party shall comply, and shall
ensure that its Affiliates, (sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the SMA Therapeutics Program, including without limitation those relating to the transport, storage,
and handling of Intrexon Materials and BioLife Products. 
 4.9 Trademarks and Patent Marking. To the extent
permitted by applicable law and regulations, BioLife shall, and shall ensure that the packaging, promotional materials, and labeling for BioLife Products shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to
BioLife’s reasonable approval of the size, position, and location thereof. Consistent with the U.S. patent laws, BioLife shall ensure that BioLife Products, or its packaging or accompanying literature as appropriate, bear applicable and
appropriate patent markings for Intrexon Patent numbers. BioLife shall provide Intrexon with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain
Intrexon’s approval thereof. BioLife’s use of the Intrexon Trademarks and patent markings shall be subject to prior review and approval of the IPC. BioLife acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and agrees
not to take any action inconsistent with such ownership. BioLife covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any BioLife Product). From time to time during
the Term, Intrexon shall have the right to obtain from BioLife samples of BioLife Product sold by BioLife or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of
inspecting the quality of such BioLife Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of such inspection to
BioLife in writing thereafter. BioLife shall comply with reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and value of the Intrexon Trademarks. 

4.10 Post-Option Exercise Obligations. From and after BioLife’s exercise of the option pursuant to Section 5.1,
BioLife shall comply with the following additional obligations: 
 (a) BioLife shall maintain at its principal place of
business or, upon notice to Intrexon, at such other place as BioLife shall determine: 
 (i) a copy of BioLife’s
certificate of incorporation or organizational document and all amendments thereto, together with executed copies of any powers of attorney pursuant to which any amendment has been executed; 

  
 20 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (ii) a copy of this Agreement; 

(iii) a copy of BioLife’s federal, state, and local income tax returns and reports, if any; and 

(iv) minutes of meetings of BioLife’s board of directors and shareholders or actions by written consent in lieu thereof, redacted
as necessary by BioLife to exclude any sensitive or confidential information that Intrexon, by operation of law or contractual stipulation, is not permitted to receive. 
 (b) BioLife shall use the accrual method of accounting in preparation of its annual reports and for tax purposes and shall keep its books and records accordingly, consistent with US GAAP.

 (c) Intrexon at its own expense and upon reasonable notice, may examine any information it may reasonably request
(including, to the extent BioLife has the right to provide such, the work papers of BioLife’s internal and independent auditors) and make copies of and abstracts from the financial and operating records and books of account of BioLife, and
discuss the affairs, finances and accounts of BioLife with BioLife and independent auditors of BioLife, all at such reasonable times and as often as Intrexon or any agents or representatives of Intrexon may reasonably request. The rights granted
pursuant to this Section 4.10(c) are expressly subject to compliance by Intrexon with the safety, security and confidentiality procedures and guidelines of BioLife, as such procedures and guidelines may be established from time to time.

 (d) As soon as available but no later than sixty (60) days after the end of each fiscal year, BioLife shall cause
to be prepared and Intrexon to be furnished with an audited balance sheet as of the last day of such fiscal year and an audited income statement, a statement of stockholders’ equity and statement of cash flows for BioLife for such fiscal year
and notes associated with each, in each case prepared in accordance with US GAAP, together with a report of BioLife’s independent auditor that such statements have been prepared in accordance with US GAAP and present fairly, in all
material respects, the financial position, results of operations and cash flows of BioLife. 
 (e) Within thirty
(30) days after the end of each calendar month and each calendar quarter, beginning with the month during which BioLife exercised the option, BioLife shall furnish the following to Intrexon an unaudited balance sheet as of the last day of such
period, and an unaudited income statement, a statement of cash flows and a statement of stockholders’ equity for BioLife for such period, in each case prepared in accordance with US GAAP. 

  
 21 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (f) As requested by Intrexon on no more than a quarterly basis, a certificate,
executed by the Executive Officer of BioLife, certifying the following: 
 (i) BioLife maintains accurate books and records
reflecting its assets and liabilities and maintains proper and adequate internal accounting controls that provide assurance that (1) transactions are executed with management’s authorization; (2) transactions are recorded as necessary
to permit preparation of the consolidated financial statements of BioLife and to maintain accountability for BioLife’s consolidated assets; (3) access to the assets of BioLife is permitted only in accordance with management’s
authorization; (4) the reporting of assets of BioLife is compared with existing assets at regular intervals; and (5) accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate procedures are
implemented to effect the collection of accounts, notes and other receivables on a current and timely basis. 
 (ii) BioLife
maintains disclosure controls and procedures to the extent such would be required of a publicly registered company under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; any such controls and
procedures are effective to ensure that all material information concerning BioLife is made known on a timely basis to those individuals responsible for the preparation of any filings that may be required to be made by Intrexon with the SEC and
other public disclosure documents. 
 (g) BioLife shall promptly prepare and furnish to Intrexon any information, whether
written or oral, requested by Intrexon that is reasonably necessary for purposes of Intrexon’s ongoing compliance with applicable law. 
 4.11 Modification of Deadlines. The parties agree that the delivery deadlines in Section 4.10 will be modified to the extent necessary to ensure that such deliverables are provided by
BioLife no less than thirty (30) days prior (inclusive of any cure period set forth in Section 10.2(a)) to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be or become
subject from time to time. Intrexon will provide BioLife with notice as promptly as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines or cure periods under this
Section 4.11. 
 ARTICLE 5 
 COMPENSATION 
 5.1 Commercialization Option.

 (a) Before expiration of the Option Period, BioLife shall have the right, subject to the requirements set forth
below, to convert this Agreement into an exclusive channel collaboration agreement and thereby become Intrexon’s exclusive channel collaborator in the Field. In partial consideration for BioLife’s appointment as an exclusive channel
collaborator and the other rights granted to BioLife hereunder, BioLife shall pay to Intrexon a technology 

  
 22 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
access fee (the “Technology Access Fee”) with a value equal to the greater of (i) the Fair Market Value of fifteen percent (15%) of the fully-diluted equity of BioLife,
as calculated using the treasury stock method in accordance with US GAAP, as of the date of exercise of the option, or (ii) Six Million Seven Hundred Fifty Thousand Dollars ($6,750,000). 

(b) “Fair Market Value” will be determined by the mutual agreement of BioLife and Intrexon. If the parties cannot
agree as to the Fair Market Value within thirty (30) days, then Fair Market Value will be determined as follows: 
 (i) If
BioLife’s equity securities are traded on a securities exchange, quotation system or comparable market, then the five-day volume-weighted average per share price of the equity securities on such exchange, quotation or market as of the date of
the option exercise multiplied by the number of equity securities of BioLife, on a fully-diluted basis as calculated using the treasury stock method in accordance with US GAAP, will be the Fair Market Value; or 

(ii) If clause (i) is not applicable, but BioLife has been evaluated by an independent appraiser, qualified to value business
enterprises such as BioLife, in the twenty-four (24) months prior to the date of the option exercise, that value will be used to determine the Fair Market Value; or 
 (iii) If neither clause (i) nor clause (ii) is applicable, or if within ten (10) business days of receipt either party disputes the Fair Market Value determined under clause
(ii) above, then BioLife and Intrexon shall cooperate to engage within ten (10) business days following notice of dispute under this clause (iii) or within ten (10) days after the Parties fail to agree under Section 5.1(b)
(as applicable) an independent appraiser qualified to value business enterprises such as BioLife who shall value BioLife, and his determination, to be made within thirty (30) days after his appointment, will be used to determine the Fair Market
Value; or 
 (iv) Either party may dispute the Fair Market Value determined by the appraiser appointed under clause
(iii) above by written notice to the other given within ten (10) business days after receiving the appraisal under clause (iii), and in such event BioLife and Intrexon shall cooperate to engage a second independent appraiser within ten
(10) business days following notice of dispute, similarly qualified, and the two appraisers shall determine, within twenty (20) days after appointment of the second appraiser, the value of BioLife, and their determination will be used to
determine the Fair Market Value. If the two appraisers cannot agree upon the Fair Market Value of BioLife, then the Fair Market Value of BioLife shall be the average of their separate determinations. 

(v) A party’s failure to give written notice of its dispute in accordance with this Section 5.1(b) will be deemed the
party’s waiver of dispute. The costs of the appraiser engaged under clause (iii) shall be paid in equal shares by BioLife and Intrexon. The cost of the second appraiser engaged under clause (iv) shall be paid by the disputing party.
The value as determined in accordance with this Section 5.1(b) shall be binding on all parties. 

  
 23 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) To execute the option, BioLife shall deliver to Intrexon prior to the
expiration of the Option Period, the following: 
 (i) In the event BioLife elects to pay the Technology Access Fee in cash,
cash equal to the Technology Access Fee. 
 (ii) In the event BioLife elects to pay the Technology Access Fee in shares of
BioLife’s equity securities: 
 1. An executed copy of the Stock Issuance Agreement (the “Stock Issuance
Agreement”) substantially in the form attached hereto as Exhibit B. 
 2. An executed copy of the
Registration Rights Agreement (together with the Stock Issuance Agreement, the “Equity Agreements”), in the form attached hereto as Exhibit C. 
 3. One or more stock certificates representing the Technology Access Fee. 

(iii) A balance sheet reviewed by BioLife’s independent accountants showing that BioLife has as of the date of execution of the
option ready access to working capital of at least five million dollars ($5M) under the SMA Therapeutics Program as well as BioLife’s projected operating expenses over the succeeding twelve (12) months. 

(iv) A certificate, executed by the Executive Officer of BioLife, certifying the items set forth under Section 4.10(f). 

5.2 Milestones. 
 (a) BioLife Equity-Based Milestone. Within thirty (30) days following the dosing of the first patient in the first Phase 2 clinical study with a BioLife Product (the “Milestone
Event”), BioLife shall pay to Intrexon a milestone fee (the “Milestone Fee”) with a value equal to the Fair Market Value of ten percent (10%) of the fully-diluted equity of BioLife, as calculated using the treasury
stock method in accordance with US GAAP, as of the date of the Milestone Event. The Milestone Fee shall be payable, at BioLife’s option, in either shares of BioLife common stock or cash. The determination of Fair Market Value shall be made
in accordance with the provisions of Section 5.1. In the event the Milestone Fee is paid in equity securities and the Technology Access Fee was paid in cash, the parties will execute in connection with such payment a stock issuance agreement
and registration rights agreement in forms substantially similar to those attached hereto as Exhibit B and Exhibit C, respectively. 
 5.3 Equity Agreements Control. All issuances of equity interests to Intrexon, or cash payments to Intrexon in lieu of equity, shall be in accordance with the terms and conditions of the
Equity Agreements, which Equity Agreements shall control to the extent they may conflict with Sections 5.1 through 5.2 of this Agreement. 

  
 24 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 5.4 Revenue Sharing. 

(a) No later than thirty (30) days after each calendar quarter in which there is positive Product Profit arising from the
sale of any BioLife Product in the Field in the Territory, BioLife shall pay to Intrexon thirty percent (30%) of such Product Profit, on a BioLife Product-by-BioLife Product basis. Commencing with the Effective Date, in the event that a
negative Product Profit occurs for a particular BioLife Product in any calendar quarter, neither BioLife nor Intrexon shall owe any payments hereunder with respect to such BioLife Product. Any negative Product Profit that results from Excess Product
Liability Costs may be carried forward to future quarters and offset against positive Product Profit in such future quarters for the same BioLife Product. Except as set forth in the preceding sentence, BioLife shall not be permitted to carry forward
any negative Product Profits to subsequent quarters. 
 (b) No later than thirty (30) days after each calendar
quarter in which BioLife or any BioLife Affiliate receives Sublicensing Revenue, BioLife shall pay to Intrexon fifty percent (50%) of such Sublicensing Revenue. 
 5.5 Method of Payment. Except for payments payable as and made in the form of equity interests, payments due to Intrexon under this Agreement shall be paid in United States dollars by wire
transfer to a bank in the United States designated in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars. 
 5.6 Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter during which Net Sales have been generated, during which Sublicensing Revenue
has been received, or during which a negative Product Profit has occurred, BioLife shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

(a) gross sales of each BioLife Product (on a country-by-country basis); 

(b) itemized calculation of Net Sales, showing all applicable deductions; 

(c) itemized calculation of Cost of Goods Sold; 
 (d) itemized calculation of Sublicensing Revenue, including any offsets claimed for Third Party license costs; 
 (e) the amount of any negative Product Profit for the applicable calendar quarter, and any negative Product Profit amount carried forward from a prior quarter and applied during the present quarter
(as per Section 5.4(a)); 
 (f) the amount of the payment (if any) due pursuant to Section 5.4(a) and/or
5.4(b); 

  
 25 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (g) the amount of taxes, if any, withheld to comply with any applicable law; and

 (h) the exchange rates used in any of the foregoing calculations. 

For three (3) years after each sale of BioLife Product or the incurring of an item included in Cost of Goods Sold, BioLife shall keep (and shall
ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales or Cost of Goods Sold (as the case may be) in sufficient detail to confirm the accuracy of the payment calculations hereunder.

 5.7 Audits. 
 (a) Upon the written request of Intrexon, BioLife shall permit an independent certified public accounting firm of internationally recognized standing selected by Intrexon, and reasonably acceptable
to BioLife, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of BioLife and its Affiliates to verify the accuracy and timeliness of the reports and
payments made by BioLife under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request. The accounting firm shall disclose to both Parties
whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in any calendar
year. 
 (b) If such accounting firm concludes that additional amounts were owed during such period, BioLife shall pay
additional amounts, with interest from the date originally due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the underpayment is greater than five percent
(5%) of the total amount actually owed for the period audited, then BioLife shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the event of overpayment, any amount
of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s); provided, however, that such credit cannot be applied to reduce the amounts payable by BioLife to Intrexon for any particular
calendar quarter by more than twenty-five percent (25%) of the amount otherwise due to Intrexon. 
 (c) Intrexon
shall (i) treat all information that it receives under this Section 5.7 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with
BioLife obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 

5.8 Taxes. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far
as reasonably possible any taxes which may be levied on any amounts payable hereunder. BioLife shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if

  
 26 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to BioLife or the appropriate governmental
authority (with the assistance of BioLife to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve BioLife of its obligation to
withhold tax, and BioLife shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that BioLife has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its
receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, BioLife withholds any amount, it shall make timely payment to the proper taxing
authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment. 
 5.9 Late Payments. Any amount owed by BioLife to Intrexon under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of
(a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 
 ARTICLE
6 
 INTELLECTUAL PROPERTY 

6.1 Ownership. 
 (a) Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with Intrexon. 
 (b) BioLife and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries, inventions, processes, techniques, and other technology, whether or not patentable, in the
course of performing the SMA Therapeutics Program (collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed written description of any such Inventions that relate to the Field. Inventorship shall
be determined in accordance with United States patent laws. 
 (c) Intrexon shall solely own all right, title and
interest in all Inventions related to Intrexon Channel Technology, together with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”). BioLife hereby assigns all of its right, title and
interest in and to the Channel-Related Program IP to Intrexon. BioLife agrees to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and
the assignment thereof. 
 (d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention,
process, technique, or other technology, whether or not patentable, that is conceived, reduced to practice or developed by BioLife solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of
the terms and 

  
 27 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
conditions of this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related
Program IP. 
 (e) All information regarding Channel-Related Program IP shall be Confidential Information of Intrexon.
BioLife shall be under appropriate written agreements with each of its employees, contractors, or agents working on the SMA Therapeutics Program, pursuant to which such person shall grant all rights in the Inventions to BioLife (so that BioLife may
convey certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the SMA Therapeutics Program. 
 6.2 Patent Prosecution. 
 (a) Intrexon shall have the sole
right, but not the obligation, to (a) conduct and control the filing, prosecution and maintenance of the Intrexon Patents, and (b) conduct and control the filing, prosecution, and maintenance of any applications for patent term extension
and/or supplementary protection certificates that may be available as a result of the regulatory approval of any BioLife Product. At the reasonable request of Intrexon, BioLife shall cooperate with Intrexon in connection with such filing,
prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall BioLife (a) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere,
that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon, (b) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any
Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or
(c) without prior approval of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or supplementary protection certificate, either in the United States or elsewhere,
that relies upon the regulatory approval of a BioLife Product. 
 (b) BioLife shall have the sole right, but not the
obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by BioLife or its Affiliates and not assigned to Intrexon under Section 6.1(c) (“BioLife Program
Patents”). At the reasonable request of BioLife, Intrexon shall cooperate with BioLife in connection with such filing, prosecution, and maintenance, at BioLife’s expense. 

(c) The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting
Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and BioLife Program Patents, as applicable. The Prosecuting Party shall: 

(i) regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s prosecution of
Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings and correspondence that the

  
 28 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Prosecuting Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may,
in lieu of directly providing copies of such information to such other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

(ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided,
however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may
have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 
 (iii) consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and BioLife
Program Patents, as applicable. 
 As used above “Prosecuting Party” means Intrexon in the case of Intrexon Patents and BioLife
in the case of BioLife Program Patents. 
 6.3 Infringement of Patents by Third Parties. 

(a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate
action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action. 
 (b) Notwithstanding the foregoing, BioLife shall have the first right, but not the obligation, to
take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by settlement
or lawsuit or other appropriate action. If BioLife fails to take the appropriate steps to enforce Product-Specific Program Patents against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to
the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by
settlement or lawsuit or other appropriate action. 
 (c) With respect to any Field Infringement that cannot reasonably
be abated through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be
obligated to choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [*****]. Intrexon and BioLife shall bear
the costs 

  
 29 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
and expenses of such enforcement equally. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult
in good faith with BioLife on such determination. For the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement.

 (d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate
with the enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and
expenses will be shared equally in accordance with terms thereof). 
 (e) BioLife shall not settle or otherwise
compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be
unreasonably withheld. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of BioLife in the Field or adversely affects any Intrexon Patent with respect to the
Field without BioLife’s prior written consent, which consent shall not be unreasonably withheld. 
 (f) Except as
otherwise agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party
controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action
initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any
action initiated by BioLife pursuant to Section 6.3(b), BioLife shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as Sublicensing Revenue. In any action initiated by Intrexon or
BioLife pursuant to Section 6.3(c), the Parties shall share the Recovery equally, and such Recovery shall not be deemed to constitute Sublicensing Revenue. 
 (g) BioLife shall promptly notify Intrexon in writing of any suspected, alleged, threatened, or actual Infringement of which it becomes aware, and Intrexon shall promptly notify BioLife in writing
of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware. 
 ARTICLE 7 

CONFIDENTIALITY 
 7.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall
not publish or otherwise disclose and shall not use for any purpose other than as provided 

  
 30 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
for in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent
evidence that specific Confidential Information: 
 (a) was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public
or otherwise part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally
available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d) was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who
had no obligation to the disclosing Party not to disclose such information to others; or 
 (e) was independently
discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party, as documented by the receiving Party’s written records. 

The foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies
as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 
 7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential Information belonging to the other Party to the extent such
disclosure is reasonably necessary in the following instances: 
 (a) complying with applicable laws or regulations or
valid court orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a
protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or for which the order was issued; 

(b) to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain regulatory approval, of
BioLife Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with reasonable opportunity to review any
such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions; 

  
 31 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) disclosure to investors and potential investors, acquirers, or merger
candidates who agree to maintain the confidentiality of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

(d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs and
clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 
 (e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be bound by obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Article 7. 
 7.3 Publicity; Publications. The Parties agree that
the public announcement of the execution of this Agreement shall be substantially in the form of a press release mutually agreed to by the Parties. Each Party will provide the other Party with the opportunity to review and comment, prior to
submission or presentation, on external reports, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer to the SMA Therapeutics Program or programs
that are approved by the Parties or, following exercise of the option contained in Section 5.1, the JSC. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar
days for review of the proposed submission or presentation. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) calendar days for review of the report or manuscript. The presenting Party will act
in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or presentations if necessary to provide the
other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. 
 7.4 Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party, subject to the exceptions set forth in Section 7.2.
Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point during the Term. Each Party shall be entitled to make such a
required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to it. In the event of any such filing, the filing
Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the
extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such comments. 

  
 32 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 7.5 Proprietary Information and Operational Audits. 

(a) For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of
Article 4, and the confidentiality obligations under Article 7, BioLife acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect BioLife’s facilities and (ii) inspect
all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to BioLife. BioLife will make
itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 
 (b) For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the confidentiality obligations under Article 7, Intrexon acknowledges that BioLife authorized
representative(s), during regular business hours may (i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five
(5) business days written notice from BioLife to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to BioLife for the aforementioned compliance review. 

(c) In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to BioLife hereunder,
Intrexon from time-to-time, but no more than quarterly, may request that BioLife confirm the status of the Intrexon Materials at BioLife (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well as any
amounts returned to Intrexon or destroyed). Within ten (10) business days of BioLife’s receipt of any such written request, BioLife shall provide the written report to Intrexon. 

7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other licensees and channel
partners or collaborators to enable BioLife to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain regulatory
approval of, BioLife Products, in a manner consistent with the provisions of Section 7.2(b). 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties of BioLife. BioLife hereby represents and warrants to Intrexon that, as of the Effective
Date: 
 (a) Corporate Power. BioLife is duly organized and validly existing under the laws of Delaware and has
full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

  
 33 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) Due Authorization. BioLife is duly authorized to execute and deliver
this Agreement and to perform its obligations hereunder, and the person executing this Agreement on BioLife’s behalf has been duly authorized to do so by all requisite corporate action. 

(c) Binding Agreement. This Agreement is a legal and valid obligation binding upon BioLife and enforceable in accordance
with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and to
limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by BioLife does not conflict with any agreement, instrument or understanding, oral or written, to which it is
a party or by which it may be bound. BioLife is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and warrants to BioLife that, as of the
Effective Date: 
 (a) Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia
and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b)
Due Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf has been duly authorized to do so by all
requisite corporate action. 
 (c) Binding Agreement. This Agreement is a legal and valid obligation binding upon
Intrexon and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to
general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement.

 (d) Additional Intellectual Property Representations. 

(i) Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to BioLife with
respect to the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents existing as of the Effective Date constitute
all of the Patents Controlled by Intrexon as of such date that are necessary for the development, manufacture or Commercialization of BioLife Products; 

  
 34 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right
or license, to any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be granted to BioLife hereunder; 
 (iv) There is no pending litigation, and Intrexon has not received any written notice of any claims or litigation, seeking to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s
rights therein; 
 (v) None of the Intrexon Patents is subject to any pending re-examination, opposition, interference or
litigation proceedings; 
 (vi) All of the Intrexon Patents have been filed and prosecuted in accordance with all applicable
laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (vii) Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of the Intrexon’s
products and technology providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other
of such persons, during the period of employment by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to BioLife herein), and Intrexon is not aware that any of
its employees or consultants is in material violation thereof; 
 (viii) To Intrexon’s knowledge, there is no
infringement, misappropriation or violation by third parties of any Intrexon Channel Technology or Intrexon IP in the Field; 

(ix) There is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that
Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written notice
of such claim; 
 (x) To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving
a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer
(A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel
Technology in the Field; 
 (xi) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s
knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable 

  
 35 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
government agency, in whole or in part, and there is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any
such Intrexon Patents; and 
 (xii) Except as otherwise disclosed in writing to BioLife, Intrexon: (A) is in material
compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of
any product that is under development, manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other
correspondence or notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the
aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not
in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the
FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA
or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or any
other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state,
local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or
were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement,
safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon’s knowledge, no third party
has initiated, conducted or intends to initiate any such notice or action. 
 except, in each of (ix) through (xii), for any instances
which would not, individually or in the aggregate, result in a material adverse effect on the rights granted to BioLife hereunder or Intrexon’s ability to perform its obligations hereunder. 

  
 36 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN
THIS ARTICLE 8 OR IN THE EQUITY AGREEMENTS, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR
NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 9 

INDEMNIFICATION 
 9.1 Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend BioLife and its Affiliates and their respective directors, officers, employees, and agents
(collectively, the “BioLife Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”)
resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from (a) the gross negligence or willful misconduct of Intrexon or any of its
Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than BioLife) or sublicensees; or (c) breach by Intrexon
of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the BioLife Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful
misconduct of BioLife or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by BioLife of a representation, warranty, or covenant of this Agreement. 

9.2 Indemnification by BioLife. BioLife agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third
Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the
relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct
of BioLife or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of BioLife or its Affiliates, licensees, or sublicensees; (c) breach by BioLife
of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any BioLife Product by or on
behalf of BioLife or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, BioLife shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the gross negligence or
willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement. 

  
 37 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 9.3 Product Liability Claims. Notwithstanding the provisions of
Section 9.2, any Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or
Commercialization of any BioLife Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”),
shall be paid by [*****], except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ Sublicensees, or any of the respective officers,
directors, employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement. 
 9.4 Control of Defense. As a condition precedent to any indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the
indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the
defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel
of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such
consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely
impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in writing. 
 9.5 Insurance. Immediately prior to, and during marketing, BioLife shall maintain in effect and good standing a product liability insurance policy issued by a reputable insurance company in
amounts considered standard for the industry. Immediately prior to, and during the conduct of any clinical trials, BioLife shall maintain in effect and good standing a clinical trials liability insurance policy issued by a reputable insurance
company in amounts considered standard for the industry. At Intrexon’s reasonable request, BioLife shall provide Intrexon with all details regarding such policies, including without limitation copies of the applicable liability insurance
contracts. BioLife shall use reasonable efforts to include Intrexon as an additional insured on any such policies. 
 ARTICLE
10 
 TERM; TERMINATION 

10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated pursuant
to Section 10.2 or 10.3 (the “Term”). 

  
 38 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 10.2 Termination for Material Breach; Termination Under Section 4.5(b)

 (a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the
other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach; provided, however, that if BioLife commits any
breach of the provisions of Section 4.10 of this Agreement, Intrexon shall have the right to terminate this Agreement if BioLife fails after notice from Intrexon to cure such breach within thirty (30) days following written notice thereof.

 (b) Intrexon shall have the right to terminate this Agreement under the circumstances set forth in Section 4.5(b)
upon written notice to BioLife, such termination to become effective sixty (60) days following such written notice unless BioLife remedies the circumstances giving rise to such termination within such sixty (60) day period. 

(c) Intrexon shall have the right to terminate this Agreement should BioLife execute any purported assignment of this Agreement
contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to BioLife and becoming effective immediately upon such written notice. 

(d) This Agreement shall terminate automatically at the end of the Option Period if by that anniversary date BioLife has not
exercised its option pursuant to Section 5.1. Intrexon will acknowledge receipt of all items delivered by BioLife under Section 5.1(c), and within five (5) business days of receipt will (i) acknowledge successful execution of the
option pursuant to Section 5.1, or (ii) identify to BioLife any material or nonmaterial defects relating to execution of the option. For purposes of this Section 10.2(d), BioLife will not be deemed to have failed to execute its option
pursuant to Section 5.1 because of any nonmaterial defect in any agreement, certificate, or instrument, or delivery thereof, required under Section 5.1(c) so long as (i) BioLife has made a bona fide attempt to meet the requirements of
Section 5.1(c) before the end of the Option Period and (ii) such nonmaterial defect is cured by BioLife within fifteen (15) days of the end of the Option Period. 

10.3 Termination by BioLife. BioLife shall have the right to voluntarily terminate this Agreement in its entirety upon
ninety (90) days written notice to Intrexon at any time, provided that such notice may not be given during the Option Period. 
 10.4 Effect of Termination. In the event of termination of this Agreement pursuant to Section 10.2 or Section 10.3, the following shall apply: 

(a) Retained Products. In the event BioLife exercised the option under Section 5.1 during the Option Period, BioLife
shall be permitted to continue the clinical development and Commercialization in the Field of any BioLife Product that, at the time of termination, satisfies at least one of the following criteria (a “Retained Product”): 

(i) the particular BioLife Product is being sold by BioLife triggering profit sharing payments therefor under Section 5.4(a) of
this Agreement, 

  
 39 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (ii) the particular BioLife Product has received regulatory approval, 

(iii) the particular BioLife Product is a subject of an application for regulatory approval in the Field that is pending before the
applicable regulatory authority, 
 (iv) the particular BioLife Product is the subject of at least an ongoing Phase 2 or Phase
3 clinical trial in the Field (in the case of a termination by Intrexon due to a BioLife uncured breach pursuant to Section 10.2(a) or a termination by BioLife pursuant to Section 10.3). 

Such right to continue development and commercialization shall be subject to BioLife’s full compliance with the payment provisions in Article 5, a
continuing obligation for BioLife to use in accord with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and commercialize any Retained Products, and all other provisions of this Agreement that survive termination. 

(b) Termination of Licenses. Except as necessary for BioLife to continue to obtain regulatory approval for, clinically
develop, use, manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to BioLife under this Agreement shall terminate and shall revert to Intrexon without
further action by either Intrexon or BioLife. BioLife’s license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 

(c) Reverted Products. All BioLife Products other than the Retained Products shall be referred to herein as the
“Reverted Products.” BioLife shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and BioLife shall not use
or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. BioLife shall immediately discontinue making any
representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 

(d) Intrexon Materials. BioLife shall promptly return, or at Intrexon’s request, destroy, any Intrexon Materials in
BioLife’s possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and Commercialization of the Retained Products in the Field. 

(e) Licenses to Intrexon. BioLife is automatically deemed to grant to Intrexon a worldwide, fully paid, royalty-free,
exclusive (even as to BioLife and its Affiliates), irrevocable, license (with full rights to sublicense) under the BioLife Termination IP, to make, have made, import, use, offer for sale and sell Reverted Products and to use the Intrexon Channel
Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive 

  
 40 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
rights held by BioLife in Reverted Products pursuant to Section 10.4(c). The Parties shall also take such actions and execute such other instruments and documents as may be reasonably
necessary to document such license to Intrexon. 
 (f) Regulatory Filings. BioLife shall promptly assign to
Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. BioLife shall also take such actions and execute such other instruments, assignments and documents
as may be necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, BioLife shall provide copies of the
portions of such regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted Products. 

(g) Data Disclosure. BioLife shall provide to Intrexon copies of the relevant portions of all material reports and data,
including clinical and non-clinical data and reports, obtained or generated by or on behalf of BioLife or its Affiliates to the extent that they relate to Reverted Products, within sixty (60) days of such termination unless otherwise agreed,
and Intrexon shall have the right to use any such Information in developing and commercializing Reverted Products and to license any Third Parties to do so. 
 (h) Third-Party Licenses. At Intrexon’s request, BioLife shall promptly provide to Intrexon copies of all Third-Party agreements under which BioLife or its Affiliates obtained a license
under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or commercialization of the Reverted Products. At Intrexon’s request such that Intrexon may Commercialize the Reverted
Products, BioLife shall promptly work with Intrexon to either (A) assign to Intrexon the Third Party agreement(s), or (B) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon
shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated with a
particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify BioLife and BioLife shall not make such assignment or grant such sublicense (or cause it to be made or granted). 

(i) Remaining Materials. At the request of Intrexon, BioLife shall transfer to Intrexon all quantities of Reverted Product
(including active pharmaceutical ingredient or work-in-process) in the possession of BioLife or its Affiliates. BioLife shall transfer to Intrexon all such quantities of Reverted Products without charge, except that Intrexon shall pay the reasonable
costs of shipping. 
 (j) Third Party Vendors. At Intrexon’s request, BioLife shall promptly provide to
Intrexon copies of all agreements between BioLife or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At Intrexon’s request, BioLife shall
promptly: (A) with respect to 

  
 41 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to Intrexon, and
(B) with respect to all other such Third Party agreements, BioLife shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. BioLife shall be liable for any costs associated with assigning a Third Party
agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to BioLife’s breach. For the avoidance of doubt, Intrexon shall have no obligation to assume any of
BioLife’s obligations under any Third Party agreement. 
 (k) Commercialization. Intrexon shall have the
right to develop and commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to BioLife, to take any such actions in connection with such activities as Intrexon (or its designee), at
its discretion, deems appropriate. 
 (l) Confidential Information. Each Party shall promptly return, or at the
other Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each
item of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive
copies on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of
BioLife) or Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with
this Section 10.4(l). 
 10.5 Surviving Obligations. Termination or expiration of this Agreement shall not
affect any rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of BioLife to pay any amount which became due and payable under the terms and conditions of this Agreement
prior to expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b), 5.5, 5.7, 6.1, 6.2 (with subsection (c) surviving
only to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or commercialized at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and
any relevant definitions in Article 1. Further, Article 7 and Sections 4.5(a), 4.5(c), 4.10, 5.2 through 5.8, and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products. 

ARTICLE 11 

DISPUTE RESOLUTION 
 11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual

  
 42 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this
Agreement (other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the
request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the
matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any disputes, controversies or differences arising from
a Committee pursuant to Article 2 shall be resolved solely in accordance with Section 2.4. 
 11.2
Arbitration. Any dispute, controversy, difference or claim which may arise between the Parties and not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating
to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding
“baseball arbitration” as follows. Either Party, following the end of the thirty (30) day period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party,
with the arbitration to be held in the state where the other Party’s principal office is located (or some other place as may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in
good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering
agreements in the pharmaceutical and biotechnology industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request
by a Party for arbitration, then each Party shall select an arbitrator meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing
criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written
proposal setting forth its proposed terms for the resolution for the matter at issue (the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide
the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to
the other Party) a response to the other Party’s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly
permitted in this Section 11.2; provided that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within
sixty (60) days after the arbitrator’s appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and
agreed principles set forth in this Agreement. The decision of the arbitrator(s) shall be final, 

  
 43 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both
Proposed Terms or award any other relief or take any other action. 
 11.3 Governing Law. This Agreement shall be
governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another
jurisdiction. 
 11.4 Award. Any award to be paid by one Party to the other Party as determined by the
arbitrator(s) as set forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by
law, be charged against the losing Party. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16,
judgment may be entered upon the final award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the
date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s)
or any court or any other forum to award consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or
exemplary damages. The only damages recoverable under this Agreement are direct compensatory damages. 
 11.5
Costs. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration. 
 11.6 Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including
a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the
arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations in Section 3.5 or Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an
adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5
or Article 7, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to, both interim and
permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise
limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 

  
 44 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 11.7 Confidentiality. The arbitration proceeding shall be confidential and
the arbitrator(s) shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the
proceedings or decision of the arbitrator(s) without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required
in connection with the enforcement of such award or as otherwise required by applicable law. 
 11.8
Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason. 
 11.9 Jurisdiction. For the purposes of this Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New York
for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts.

 11.10 Patent Disputes. Notwithstanding any other provisions of this Article 11, and subject to the provisions
of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was filed or
granted. 
 ARTICLE 12 
 GENERAL PROVISIONS 
 12.1 Use of
Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement, except that
(a) either Party may use the name of the other Party as required by regulations and in press releases accompanying quarterly and annual earnings reports approved by the issuer’s Board of Directors, and (b) BioLife may use the Intrexon
Trademarks in accord with licenses and restrictions set forth herein. 
 12.2 LIMITATION OF LIABILITY. NEITHER
PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE
FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 

  
 45 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.3 Independent Parties. The Parties are not employees or legal
representatives of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a
joint venture, partnership, or business organization of any kind. 
 12.4 Notice. All notices, including notices
of address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms
receipt of such transmission with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage
prepaid, return receipt requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: President, Human Therapeutics Division
 Fax: (301) 556-9901

		
	 with a copy to:
	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Legal Department
 Fax: (301) 556-9902

		
	If to BioLife:	  	 BioLife Cell Bank, Inc.
 11970
N. Central Expressway
 Suite 280

Dallas, TX 75243
 Attention: Chief Executive
Officer

		
	with a copy to:	  	[*****]

 12.5 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

  
 46 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.7 Entire Agreement; Amendment. This Agreement, including any exhibits
attached hereto, constitute the entire, final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior
confidentiality agreement between the Parties). All information of Intrexon or BioLife to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by
such other Party under the obligations set forth in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

12.8 Non-assignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations
under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent
(a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets, provided
that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators
and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization, or similar transaction,
or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual
property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed to the other Party under this Agreement. 

12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its obligations under this
Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes, governmental
regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 

12.11 Non-Solicitation. During the Term and for a period of one (1) year following the end of the Term, neither
BioLife nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment with, or hire any employee of the other Party or an individual who was employed by the other party with one
(1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment solicitations or advertisements shall not be considered direct or indirect solicitations, and are not prohibited under
this Agreement. 

  
 47 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.12 Legal Compliance. The Parties shall review in good faith and
cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 
 12.13
Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of electronic communication), each of which taken together will constitute one and the same instrument, and any of the
Parties hereto may execute this Agreement by signing any such counterpart. 
 [Remainder of page intentionally left blank.]

  
 48 

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this Exclusive Research Collaboration Agreement. 
  

									
	INTREXON CORPORATION	 		 	BIOLIFE CELL BANK, INC.
					
	By:	 	 /s/ Jayson M. Rieger
	 		 	BY:	 	 /s/ John D. Harkey, Jr.

					
	Name:	 	Jayson M. Rieger, Ph.D.	 		 	Name:	 	John D. Harkey, Jr.
					
	Title:	 	President of Human Therapeutics Division and Senior Vice President	 		 	Title:	 	Chairman of the Board
					
		 		 		 	BY:	 	 /s/ David G. Genecov

					
		 		 		 	Name:	 	David G. Genecov, M.D.
					
		 		 		 	Title:	 	President
					
		 		 		 	BY:	 	 /s/ John A Carbona

					
		 		 		 	Name:	 	John A. Carbona
					
		 		 		 	Title:	 	Chief Executive Officer

 SIGNATURE PAGE TO EXCLUSIVE RESEARCH COLLABORATION AGREEMENTExhibit 10.16

 Exhibit 10.16 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
 COLLABORATION AND LICENSE AGREEMENT

 THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of June 6, 2011 (the
“Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and INTREXON CORPORATION, a Virginia corporation (“Intrexon”). 

WHEREAS, Halozyme is the owner or exclusive licensee of certain patents, formulations and know-how related to the PH20 Drug (as defined
below); 
 WHEREAS, Intrexon is the owner or exclusive licensee of certain intellectual property related to the Intrexon
Biologic (as defined below); 
 WHEREAS, Intrexon may seek one or more drug designations in the United States or elsewhere for
products derived from or related to the Intrexon Biologic; and 
 WHEREAS, the parties desire to enter into a collaborative
relationship in which the parties will collaboratively develop, and Halozyme will license to Intrexon the right to commercialize, the Product in the Licensed Field in the Territory (each as defined below), all on the terms and conditions of this
Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties
hereby agree as follows: 
  

	 	1.	DEFINITIONS. 

 1.1
“Affiliate” shall mean, with respect to a party, any entity that controls or is controlled by such party, or is under common control with such party. For purposes of this definition, an entity shall be deemed to control another
entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity (or other comparable interest for an entity other than a corporation). 

1.2 “API” shall mean the bulk formulation of PH20 Drug [*****]. 

1.3 “API Specifications” shall mean the specifications for the API set forth in Schedule 1.3. 

1.4 “BLA/MAA” shall mean a Biologics License Application (“BLA”) submitted to the FDA or a Market
Authorization Application (“MAA”) submitted to the EMA or MHLW, or any supplemental filing to a BLA or MAA. 

1.5 “cGMP” shall mean the principles detailed in the United States Current Good Manufacturing Practices (21 CFR 200, 211
and 600), the “Rules Governing Medicinal Product in The European Community – Volume IV Good Manufacturing Practice for Medicinal Products,” and/or “Cooperative Manufacturing Arrangements for Licensed Biologics” FDA-CBER.

  
 1 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.6 “Clinical Trial” shall mean any human clinical trial in any country
the results of which are to evaluate or establish safety, efficacy or dosing, including without limitation pursuant to 21 CFR 312.21, et seq. A “Phase III Clinical Trial” shall mean a pivotal human clinical trial in any
country the results of which could be used to establish safety and efficacy of a Product as a basis for a BLA/MAA or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent. 

1.7 “CMO” shall mean contract manufacturing organization. 

1.8 “Collaboration Invention” shall mean any invention or discovery, whether or not patentable (including a
modification, improvement or new use), that is first conceived or reduced to practice pursuant to Halozyme’s activities, Intrexon’s activities or both parties’ joint activities that is related to the Intrexon Biologic, the PH20 Drug
and/or the combination of both, in each case during the term of this Agreement and in connection with work conducted under the Workplan. 
 1.9 “Collaboration Supported Patents” shall mean (a) all patent applications filed after the Effective Date which claim, and only to the extent it claims, a Collaboration Invention;
(b) all patents that have issued or in the future issue from any of the foregoing patent applications, including without limitation utility models, design patents and certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, re-examinations, extensions or term additions to any such patents and patent applications. 
 1.10 “Collaboration Supported PH20 Patents” shall mean all Collaboration Supported Patents to the extent claiming or covering PH20 Drug [*****] alone or in combination with any molecule
or biologic, but excluding the Collaboration Supported Product Patents. 
 1.11 “Collaboration Supported Product
Patents” shall mean all Collaboration Supported Patents to the extent claiming or covering a Collaboration Invention with respect to PH20 Drug [*****] combined with the Intrexon Biologic. 

1.12 “Collaboration Supported Intrexon Biologic Patents” shall mean all Collaboration Supported Patents to the extent
claiming or covering the Intrexon Biologic, but excluding the Collaboration Supported Product Patents. 
 1.13
“Confidential Information” shall mean all information and data that (a) is provided by one party to the other party under this Agreement, and (b) if disclosed in writing or other tangible medium is marked or identified as
confidential at the time of disclosure to the recipient, is acknowledged at the time of disclosure to be confidential, or otherwise should reasonably be deemed to be confidential. Notwithstanding the foregoing, Confidential Information of a party
shall not include that portion of such information and data which, and only to the extent, the recipient can establish by written documentation: (i) is known to the recipient as evidenced by its written records before receipt thereof from the
disclosing party, (ii) is disclosed to the recipient free of confidentiality obligations by a third person who has the right to make such disclosure, (iii) is or becomes part of the public domain through no fault of the recipient, or
(iv) the recipient can reasonably establish is independently developed by persons on behalf of recipient without use of the information disclosed by the disclosing party. 

  
 2 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.14 “cover” or “covering” as used in relation to a
patent or patent right shall include composition of matter claims as well as methods of manufacture or use. 
 1.15
“DMF” shall mean a Drug Master File filed with the FDA, EMA, MHLW or another foreign equivalent. 
 1.16
“EMA” shall mean the European Medicines Agency of the European Union, or the successor thereto. 
 1.17
“Excluded Fields” shall mean [*****]. 
 1.18 “Exclusive Biologic” shall mean, with respect to
the Exclusive Field, any molecule or biologic which (1) as of the Effective Date is currently in clinical development to evaluate such product’s safety or efficacy for use in the Exclusive Field, or is commercialized for use in the
Exclusive Field, and (2) after the Effective Date may at any time during the term of this Agreement be the subject of a clinical study specifically designed to evaluate such product’s safety or efficacy for use in the Exclusive Field.

 1.19 “Exclusive Field” shall mean genetic emphysema. 

1.20 “FDA” shall mean the United States Food and Drug Administration, or any successor entity thereto. 

1.21 “First Commercial Sale” shall mean the first sale of the Product by Intrexon, its sublicensee or their respective
Affiliates to customers who are not Affiliates in any country after all applicable marketing approvals (if any) have been granted by the applicable governing health authority. 
 1.22 “FTE” shall mean a full time equivalent of an employee for one calendar year. 
 1.23 “Fully Burdened Manufacturing Cost” shall mean Halozyme’s fully burdened cost to manufacture (or acquire from its third party manufacturer) and supply API, including without
limitation costs for testing, packaging, shipping and an allocable share of corporate and overhead costs. 
 1.24 “Fully
Burdened Workplan Cost” shall mean the cost to conduct the research and development activities to be conducted by Halozyme as set forth in the Workplan calculated on an FTE basis at a rate through the first [*****] years of the Agreement at
[*****] dollars ($[*****]) per FTE, subject to increase thereafter based on the Producer Price Index for Finished Goods Less Food and Energy (PPILFE), published by the United States Department of Labor in the monthly Labor Review. 

  
 3 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.25 “Grantback Patent” shall mean any issued patent owned or
controlled by Intrexon at any time during the term of this Agreement that claims the composition, manufacture or use of PH20 Drug [*****] alone or in combination with any other biologic or molecule, but not to the extent claiming the Intrexon
Biologic. 
 1.26 “Halozyme In-License” shall mean a license, sublicense or other agreement under which
Halozyme has acquired, or hereafter acquires, rights to the Licensed IP Rights. Schedule 1.26 sets forth a true and correct list as of the Effective Date of the Halozyme In-Licenses. 

1.27 “IND” shall mean an Investigational New Drug application or similar application required to commence human clinical
testing of a product submitted to the FDA, or its foreign equivalent. 
 1.28 “Intrexon Biologic” shall mean
that certain alpha-1 anti-trypsin molecule with the amino acid sequence set forth on Schedule 1.28, including any analogs, splice variants, glycoforms, truncated forms, muteins, fusions for extending half life or for purification
purposes, point mutations or other derivatives of such inhibitor, whether human or recombinant, provided in each case that (i) such molecule retains at least 25% of the specific activity of purified alpha-1 anti-trypsin molecule with the amino
acid sequence set forth in Schedule 1.28, and determined in a human pancreatic elastase assay (ENZO Neutrophil Elastase Colorimetric Drug Discovery Kit) (or such other assay as demonstrated by Intrexon to Halozyme’s reasonable
satisfaction to be scientifically valid), and (ii) such molecule does not have greater than 0.8 units of activity per milligram of protein, where a unit is the amount of C1-inhibitor activity present in one (1) milliliter of normal, human
plasma, as measured by the Behrichrom C-1 inhibitor assay (in accordance with the instructions provided with such assay) or such other assay as demonstrated by Halozyme to Intrexon’s reasonable satisfaction to be scientifically valid

 1.29 “Intrexon Subcutaneous Product” shall mean the Intrexon Biologic administered through a subcutaneous
mode of administration for use with any indication in the Licensed Field, but excluding the Product. 
 1.30 “Licensed
Field” shall mean the diagnosis, prevention, management or treatment of any disease state or condition in humans, but excluding the Excluded Fields. 
 1.31 “Licensed IP Rights” shall mean, collectively, the Licensed Know-How Rights, Licensed Patent Rights and Licensed Marks. 

1.32 “Licensed Know-How Rights” shall mean all of Halozyme’s rights (including Halozyme’s grantback rights
from third parties to the extent sublicensable) in all trade secret and other know-how relating to PH20 Drug [*****] that are necessary or useful to develop, obtain regulatory approval for, manufacture, commercialize or use Products in the Licensed
Field. 
 1.33 “Licensed Marks” shall mean those certain trademarks, trade names, designs and markings owned or
licensed by Halozyme and designated from time to time in writing by Halozyme for use by Intrexon under this Agreement in connection with the packaging, labeling, promotion and marketing of Products in the Licensed Field. 

  
 4 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.34 “Licensed Patent Rights” shall mean all of Halozyme’s rights
(including Halozyme’s grantback rights from third parties to the extent sublicensable) in (a) all patent applications heretofore or hereafter filed that claim or cover PH20 Drug [*****] alone or in combination with any other composition,
as necessary or useful to develop, obtain regulatory approval for, manufacture, commercialize or use Products in the Licensed Field, (b) all patents that have issued or in the future issue from any of the foregoing patent applications,
including without limitation utility models, design patents and certificates of invention, and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patents and patent applications.
For clarity, Licensed Patents Rights include Collaboration Supported PH20 Patents. 
 1.35 “MHLW” shall mean
the Ministry of Health, Labour and Welfare of Japan, or the successor thereto. 
 1.36 “Net Sales” shall mean
the gross sales price of the Product invoiced by Intrexon, its sublicensee or their respective Affiliates to customers who are not Affiliates (or who are Affiliates but are the end users of the Product) less, to the extent actually paid or accrued
by Intrexon, its sublicensee or their respective Affiliates (as applicable): (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for Product; (b) packaging, freight and insurance costs
incurred by Intrexon, its sublicensee or their respective Affiliates (as applicable) in transporting Product to such customers; (c) cash, quantity and trade discounts, rebates, assessments and other price reductions for Product given to such
customers under price reduction programs that are consistent with price reductions given for similar products by Intrexon, its sublicensee or their respective Affiliates (as applicable); (d) sales, use, value-added and other direct taxes
incurred on the sale of Product to such customers; (e) customs duties, surcharges and other governmental charges incurred in exporting or importing Product to such customers; (f) the amount of any [*****] up to a maximum of [*****] as
calculated under clauses (a) – (e) above on a quarterly basis; and (g) any adjustments substantially similar to any of the foregoing. 
 1.37 “PH20 Drug” shall mean the active compound, recombinant human PH20 hyaluronidase (i.e. a truncated form of native human PH20 hyaluronidase consisting of residues 36-482, inclusive,
of the native human PH20 hyaluronidase). 
 1.38 “ [*****]” shall mean a [*****] that consists of any
improvement or enhancement to [*****] and intended to [*****]. 
 1.39 “Prior Collaborations” shall have the
meaning ascribed to it in Section 2.2.1. 
 1.40 “Product” shall mean a product that includes (a) the
Intrexon Biologic (and, except as otherwise set forth below, no other active pharmaceutical ingredients), and (b) PH20 Drug supplied by Halozyme [*****] to Intrexon pursuant to this Agreement 

([*****]), as an active ingredient/excipient for enhancing the dispersion and/or absorption of the Intrexon Biologic, in any liquid injectable
formulation, and/or any 

  
 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
lyophilized formulation, which product is promoted, marketed and sold in a co-formulation (e.g., pre-formulated together in a single solution in a single container, in a single package with a
single label at a single price). For the avoidance of doubt, the addition of any excipient or adjuvant to the product shall not render such product outside the definition of Product. 

1.41 “Royalty Term” shall mean, with respect to each country, the period equal to the longer of (a) if, at the time
of the First Commercial Sale of Product in such country, the use, offer for sale, sale or import of Product in such country would infringe a Valid Claim, the term for which such Valid Claim remains in effect and would be infringed, and
(b) ten (10) years following the date of the First Commercial Sale of Product in such country. 
 1.42
“SEC” shall have the meaning ascribed to it in Section 2.1.1. 
 1.43 “Valid Claim” shall
mean a claim of an issued and unexpired patent included within the Licensed Patent Rights or the Collaboration Supported Product Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 

1.44 “Workplan” shall have the meaning set forth in Section 5.1.2. 

 

	 	2.	REPRESENTATIONS, WARRANTIES AND COVENANTS. 

 2.1 By Each Party. Each party represents and warrants to the other party as follows: 
 2.1.1 Organization. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized. 

2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 
 2.1.3 Consents. All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by such party in connection with this
Agreement have been obtained. 
 2.1.4 No Conflict. The execution and delivery of this Agreement and the performance of
such party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not conflict with, or constitute a default under, any contractual
obligation of such party. 
 2.1.5 No Debarment. In the course of the development of the Product, neither party shall
use, during the Term, any employee or consultant who has been debarred by any regulatory authority, or, to the best of such party’s knowledge, is the subject of debarment proceedings by a regulatory authority. 

  
 6 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 2.2 By Halozyme. Halozyme further represents and warrants to Intrexon as follows:

 2.2.1 Licensed Patent Rights; Licensed IP Rights. As of the Effective Date, the Licensed Patent Rights have not been
held by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. As of the Effective Date, except as expressly set forth under the heading “Risks Related To Our Industry” in Halozyme’s Form 10-K for the
year ending December 31, 2010 filled with the Securities and Exchange Commission (“SEC”), Halozyme has not received written notice of any claim or litigation by any third party alleging that any of the Licensed Patent Rights
are invalid or unenforceable. Halozyme has the right to grant the licenses under the Licensed IP Rights pursuant to this Agreement. 
 (a) Schedule 2.2.1(a) sets forth a true and complete list of all Licensed Patent Rights as of the Effective Date, and indicates the current status, date and country of filing and issuance.

 (b) [*****] 
 (c) Neither Halozyme nor any of its Affiliates has received any written notice from any person that the use or practice of the Licensed Patent Rights or Licensed Know-How Rights infringes or
misappropriates the intellectual property rights of a third party. 
 (d) [*****] 

(e) All current and former employees and consultants of Halozyme and its Affiliates who are or have been substantively involved in the
design, review, evaluation or development of the Licensed Patent Rights or Licensed Know-How Rights have executed written contracts or are otherwise obligated to protect the confidential status and value thereof and to vest in Halozyme or its
Affiliates exclusive ownership of the Licensed Patent Rights and Licensed Know-How Rights. 

  
 7 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (f) The Halozyme In-Licenses, as set forth on Schedule 1.26, sets forth a
true and complete list of all agreements to which Halozyme is a party that are necessary or useful for the manufacture, use, sale or importation of PH20 Drug, copies of which have been provided by Halozyme to Intrexon, subject to redaction of
confidential or proprietary information provided, however, that such redaction does not unreasonably interfere with Intrexon’s understanding of the relevant sections of such agreements. Halozyme has fulfilled all of its obligations and is not
in breach or default under such agreements and has not waived or allowed to lapse or terminate any of its rights thereunder. 

2.2.2 Halozyme In-Licenses. Halozyme has not received notice of breach or termination of the Halozyme In-Licenses. 

2.2.3 SEC Reports. To Halozyme’s knowledge, neither Halozyme’s Report on Form 10-K for the year ended December 31,
2010, nor any other document filed by Halozyme with the SEC since March 11, 2011, contained a misstatement of a material fact, or failed to state a material fact required to be stated therein or necessary to make the statements made therein not
misleading, as of the date such filing was made, in each case relating to the Licensed Patent Rights and Licensed Know-How Rights. 
 2.2.4 API Specifications. The API Specifications set forth on Schedule 1.3 hereto are consistent with the specifications for API to be provided under the Prior Collaborations. Halozyme’s
present manufacturing process has produced PH20 Drug with qualities that meet the API Specifications. 
 2.3 DISCLAIMER OF
WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH ABOVE OR IN SECTION 7.7, HALOZYME MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE LICENSED IP RIGHTS, INCLUDING WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY
REGARDING VALIDITY, ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT. 
  

	 	3.	LICENSE. 

 3.1 License
Grant to Intrexon. 
 3.1.1 On the terms and conditions of this Agreement, Halozyme hereby grants to Intrexon an exclusive
worldwide license under the Licensed IP Rights (with the limited right to sublicense pursuant to Section 3.1.2) to develop, make, have made, use, offer for sale, sell and import Products for use in the Licensed Field. Except as expressly set
forth in this Agreement, Intrexon shall not use the Licensed IP Rights for any other use. 
 3.1.2 Intrexon shall have the
right to grant sublicenses to (a) third parties solely for the purpose of developing, manufacturing or commercializing such Product in each case jointly with, or for the benefit of, Intrexon and (b) Affiliates. Intrexon shall provide
Halozyme with a copy of each sublicense referenced in clause (a) and prompt notice of each sublicense referenced in clause (b), subject to redaction of confidential or proprietary information provided, however, that such redaction does not
unreasonably interfere with Halozyme’s understanding of the relevant sections of such sublicenses. Any such sublicense 

  
 8 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
shall be subject and subordinate to the terms and conditions of this Agreement. Intrexon hereby represents that it has the power to bind its Affiliates to the terms and conditions set forth in
this Agreement and any Affiliate that receives a sublicense shall be bound by the terms and conditions of this Agreement as if such Affiliate was an original signatory to this Agreement. Notwithstanding the foregoing, Intrexon shall remain liable
for a breach of this Agreement by its Affiliate and shall remain responsible for all payments due to Halozyme hereunder. 
 3.2
No Implied Licenses. Only licenses and rights expressly granted herein shall be of legal force and effect. No license or other right shall be created hereunder by implication, estoppel or otherwise. 

3.3 Exclusivity. 
 3.3.1 Commencing on the Effective Date, neither Halozyme nor any of its Affiliates shall grant to any third party any right to develop, make, have made, use, offer for sale, sell or import any product
that consists of PH20 Drug [*****] together with an Exclusive Biologic for use in the Exclusive Field. 
 3.3.2 Commencing on
the Effective Date, neither Halozyme nor any of its Affiliates shall grant to any third party any right to develop, make, have made, use, offer for sale, sell or import any product that consists of PH20 Drug [*****] together with the Intrexon
Biologic (with or without any additional active pharmaceutical ingredients) for use in the Licensed Field. 
 3.3.3 Neither
Halozyme nor its Affiliates shall sell or enter into any agreement with any third party to sell PH20 Drug [*****] with an Exclusive Biologic in a kit (i.e., the PH20 Drug [*****] and the biologic or molecule are in separate containers, but packaged
together and at a single price) for use in the Exclusive Field. 
 3.3.4 Halozyme shall include in any future agreements with a
third party to develop, make, have made, use, offer for sale, sell or import any product that consists of PH20 Drug [*****] (including products sold as a kit with PH20 Drug or [*****] a covenant prohibiting such third party from using such product
in the Exclusive Field. 
 3.3.5 For the avoidance of doubt, nothing in this Agreement shall restrict Halozyme from granting
rights to a Third Party for PH20 Drug [*****] combined with an Exclusive Biologic (except for the Intrexon Biologic) outside the Exclusive Field. 
 3.4 Excluded Fields. Intrexon shall not seek regulatory approval of the Product, or use or commercialize the Product, for use in any of the Excluded Fields. 

 

	 	4.	FINANCIAL TERMS. 

 4.1
License Fee. Within [*****] business days of the Effective Date, Intrexon shall pay to Halozyme the nonrefundable and noncreditable initial license fee of nine million dollars ($9,000,000). 

  
 9 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 4.2 Exclusivity Fee. Commencing with the first anniversary of the Effective Date,
and continuing with each successive anniversary until the initiation of the first Phase III Clinical Trial for the Product, Intrexon shall pay to Halozyme the non-refundable and non-creditable exclusivity fee of [*****] dollars ($[*****]).

 4.3 Milestone Payments. 
 4.3.1 Within thirty (30) days following the achievement of each of the following development milestones, Intrexon shall give written notice to Halozyme and shall pay to Halozyme the corresponding
non-refundable and non-creditable milestone payments: 
 (i) $[*****] [*****]; 

(ii) $[*****] [*****]; 
 (iii) $[*****] [*****]; 
 (iv) $[*****] [*****]; 

(v) $[*****] [*****]; 
 (vi) $[*****] [*****]; 
 (vii) $[*****] [*****]; 

(viii) $[*****] [*****]; 
 (ix) $[*****] [*****]; 
 (x) $[*****] [*****]; 

(xi) $[*****] [*****]; 
 (xii) $[*****] [*****] 
 (xiii) $[*****] [*****]. 

  
 10 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 If for whatever reason (other than due to a breach by Intrexon) a milestone payment set forth above is
not paid for a Product and the subsequent development event that corresponds to the same indication and to the same country or jurisdiction is achieved for such Product (for example, doing a [*****]), then both the then-achieved milestone payment
and the prior unpaid milestone payment shall be payable at the time the then-achieved milestone payment is made. Except for those milestone payments that are due for each disease or indication other than the Exclusive Field, each milestone payment
shall be payable only one (1) time, regardless of the number of times that the corresponding event is achieved. If the development of a Product is terminated under this Agreement (“Terminated Product”) for any reason and
another Product is developed under this Agreement and then achieves an event giving rise to a milestone payment, such milestone payment shall not be made if it had previously been made with respect to the Terminated Product. 

4.4 Royalties. 
 4.4.1 During the applicable Royalty Term, Intrexon shall pay to Halozyme royalties on annual Net Sales by Intrexon, its sublicensees and their respective Affiliates in any country equal to
(a) [*****] of the first [*****] dollars ($[*****]) of such annual Net Sales, (b) [*****] of such annual Net Sales in excess of [*****] dollars ($[*****]) up to and including [*****] dollars ($[*****]), (c) [*****] of such annual Net
Sales in excess of [*****] dollars ($[*****]) up to and including [*****] dollars ($[*****]), and (d) eleven percent (11%) of such annual Net Sales in excess of [*****] dollars ($[*****]). In any country where either (i) there is no
Valid Claim that would be infringed by the making, using, selling, offering for sale or importation of the Product (for clarity, a Valid Claim may be included in the Licensed Patent Rights or the Collaboration Supported Product Patents, so long as
it would be infringed by the making, using, selling, offering for sale or importation of the Product in such country), or [*****], then the foregoing royalty rate in such country shall be reduced by [*****] with respect to applicable Net Sales in
such country. 
 4.4.2 If Intrexon, its sublicensees or their respective Affiliates sells a Product to a third party who also
purchases other products or services from Intrexon, its sublicensees or their respective Affiliates, and Intrexon, its sublicensees or their respective Affiliates discounts the purchase price of such Product to a greater degree than it generally
discounts the price of its other products or services to such customer, then in such case the Net Sales for the sale of such Product to such third party shall equal the arm’s length price that third parties would generally pay for the Product
alone when not purchasing any other product or service from Intrexon, its sublicensee or their respective Affiliates. For purposes of this provision, “discounting” includes establishing a price for a Product at a discount of [*****] or
more from the average sales price for the applicable country of end use or for the applicable region if sales are conducted on a regional basis. 

  
 11 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 4.5 API Price. For all API supplied by Halozyme under Article 7, Intrexon
shall pay to Halozyme a price equal to [*****] percent ([*****]%) of the Fully Burdened Manufacturing Cost to Halozyme to manufacture (or have manufactured), store and supply API. As of the date of this Agreement, the Fully Burdened
Manufacturing Cost to Halozyme of the API is reasonably estimated at $[*****]/milligram. Halozyme shall invoice Intrexon for all API upon shipment in accordance with Article 7, and Intrexon shall pay each such invoice unless contested within
[*****] days after receipt. 
 4.6 Royalty Reports. 

4.6.1 Within [*****] days after the end of the first, second and third calendar quarters of each calendar year and within [*****]
days after the end of the fourth quarter during each calendar year, commencing with the calendar quarter in which there is a first commercial sale of a Product, to the extent such information is reasonably available, Intrexon shall furnish to
Halozyme a written report showing in reasonably specific detail, on a country-by-country basis, (a) the quantity and aggregate gross sales of all Products sold by Intrexon, its sublicensees and their respective Affiliates during such calendar
quarter and the calculation of Net Sales from such gross sales; (b) the calculation of the royalties, if any, which shall have accrued based upon such Net Sales; (c) the withholding taxes, if any, required by law to be deducted with
respect to such sales; and (d) the exchange rates, if any, used in determining the amount of United States dollars. 

4.6.2 With respect to sales of Products invoiced in United States dollars, all such amounts shall be expressed in United States dollars.
With respect to sales of Products invoiced in a currency other than United States dollars, all such amounts shall be expressed both in the currency in which the sale is invoiced and in the United States dollar equivalent. The United States dollar
equivalent shall be calculated using the average of the exchange rates (local currency per US$1) published in The Wall Street Journal, Western Edition, under the heading “Currency Trading” on the last business day of each month in
the applicable calendar quarter. All royalties payable hereunder shall be calculated based on Net Sales expressed in United States dollars. 
 4.6.3 Intrexon shall keep, to the extent such information is reasonably available, complete and accurate records in sufficient detail to properly reflect all gross sales and Net Sales and to enable the
royalties payable to be determined. 
 4.6.4 All royalties shown to have accrued by each royalty report provided under this
Section 4.6 shall be payable on the date such royalty report is due. Payment of royalties in whole or in part may be made in advance of such due date. 
 4.7 Audits. 
 4.7.1 Upon the written request of Halozyme and not more than
once in every two years, Intrexon shall permit an independent certified public accounting firm of nationally recognized standing, selected by Halozyme and reasonably acceptable to Intrexon, to have access during normal business hours to such records
of Intrexon as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more 

  
 12 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
than [*****] months prior to the date of such request and which have not previously been audited. The accounting firm shall disclose to Halozyme only whether the reports are correct and the
specific details of any discrepancy, but no other information shall be shared. If such accounting firm concludes that additional royalties were owed during the audited period, or that excess royalties were paid during the audited period, Intrexon
shall pay such additional royalties, or Halozyme shall provide Intrexon with a credit for such excess royalties, as the case may be, within [*****] days of the date Halozyme delivers to Intrexon such accounting firm’s written report so
concluding; provided, that, in the case of a credit, if Intrexon is unable to use the full amount of such credit within [*****] months from the date of such report, then Halozyme shall promptly pay to Intrexon the unused amount of such credit. The
fees charged by such accounting firm shall be paid by Halozyme; provided, however, if the audit discloses that the royalties payable by Intrexon for such period are more than [*****] percent ( [*****]%) of the royalties actually paid for such
period, then Intrexon shall pay the reasonable fees and expenses charged by such accounting firm. Halozyme shall treat all financial information subject to review under this Section 4.7.1 as confidential, and shall cause its accounting firm to
retain all such financial information in confidence and shall be liable to Intrexon for any improper disclosure by its accounting firm. 
 4.7.2 Upon the written request of Intrexon and not more than once in every two years, Halozyme shall permit an independent certified public accounting firm of nationally recognized standing, selected by
Intrexon and reasonably acceptable to Halozyme, to have access during normal business hours to such records of Halozyme as may be reasonably necessary to verify the accuracy of each of the API transfer price and the Workplan costs hereunder for any
year ending not more than [*****] months prior to the date of such request and which have not previously been audited. The accounting firm shall disclose to Intrexon only whether the API transfer price and/or the Workplan cost was correct and the
specific details of any discrepancy, but no other information shall be shared. If such accounting firm concludes that Halozyme overcharged for the API transfer price and/or the Workplan cost during the audited period, or that Halozyme undercharged
for the API transfer price and/or the Workplan cost during the audited period, Halozyme shall provide Intrexon with a credit for such overcharge, or Intrexon shall make an additional payment in respect of such undercharge, within [*****] days of the
date Intrexon delivers to Halozyme such accounting firm’s written report so concluding; provided, that, in the case of a credit, if Intrexon is unable to use the full amount of such credit within [*****] months from the date of such report,
then Halozyme shall promptly pay to Intrexon the unused amount of such credit. The fees charged by such accounting firm shall be paid by Intrexon; provided, however, if the audit discloses that the API transfer price and/or the Workplan cost charged
by Halozyme for such period was more than [*****] percent ([*****]%) of the API transfer price and/or the Workplan cost, as the case may be, actually due for such period, then Halozyme shall pay the reasonable fees and expenses charged by such
accounting firm. Intrexon shall treat all financial information subject to review under this Section 4.7.2 as confidential, and shall cause its accounting firm to retain all such financial information in confidence and shall be liable to
Halozyme for any improper disclosure by its accounting firm. 
 4.8 Withholding Taxes. Intrexon shall be entitled to
deduct from the royalty payments otherwise due to Halozyme hereunder the amount of any withholding taxes, value-added taxes or other taxes, levies or charges with respect to such royalty payments that are

  
 13 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
required to be withheld by Intrexon. Intrexon shall pay to the appropriate governmental authority on behalf of Halozyme such taxes, levies or charges that are withheld. Intrexon shall use
reasonable efforts to take such action as may be reasonably requested by Halozyme, and at Halozyme’s cost, to minimize any such taxes, levies or charges required to be withheld on behalf of Halozyme by Intrexon, provided that such actions do
not, or could not reasonably be expected to, adversely affect or impact Intrexon or any of its Affiliates. Intrexon promptly shall deliver to Halozyme proof of payment of all such taxes, levies and other charges, together with copies of all
communications from or with such governmental authority with respect directly related thereto. 
 4.9 Payment Method. All
payments by Intrexon to Halozyme hereunder shall be in United States Dollars in immediately available funds (or funds that will be available on or prior to the date such payment is due) and shall be made by wire transfer to such bank account as
designated from time to time by Halozyme to Intrexon. Except with respect to any amounts disputed in good faith, any late payments due hereunder shall bear interest at the rate of [*****]% per month, or the maximum allowable by law if less.

  

	 	5.	PRODUCT DEVELOPMENT AND COMMERCIALIZATION. 

 5.1 Responsibility. 
 5.1.1 Except as otherwise set forth in this
Section 5.1, Intrexon shall be solely responsible, at its sole cost, for conducting the development, manufacture, regulatory approval and commercialization of Products, and shall own all clinical data, regulatory applications, filings,
approvals and licenses for each Product. 
 5.1.2 Intrexon shall engage Halozyme to conduct development and regulatory work for
the PH20 Drug component of each Product and for providing technical assistance regarding the development of each Product. All such activities by Halozyme shall be conducted at the reasonable request of Intrexon pursuant to a mutually acceptable
written workplan that is customary in the industry (the “Workplan”). Following the end of each calendar quarter, Halozyme shall invoice Intrexon for the Fully Burdened Workplan Cost to Halozyme to conduct such activities, and
Intrexon shall pay each such invoice within [*****] days after receipt. 
 5.1.3 Halozyme shall provide Intrexon with a full
dossier for the PH20 Drug for Intrexon’s use in BLA/MAA filings. Such dossier will include chemistry manufacturing and controls sections and pre-clinical pharmacology and toxicology sections. Upon written request from Intrexon, Halozyme will
file a DMF for the PH20 Drug as promptly as practicable. Halozyme shall own the DMF for the PH20 Drug component of each Product. Intrexon shall have the right to cross-reference such DMF. In countries where this is not feasible, Halozyme shall
provide Intrexon, at Intrexon’s cost, with such information in Halozyme’s control regarding the PH20 Drug component of each Product as is reasonably necessary for Intrexon to include in the applicable regulatory applications for such
Product. Halozyme shall promptly notify Intrexon of any changes to the dossier or DMF for the PH20 Drug. 

  
 14 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.1.4 Promptly following the Effective Date, each party shall appoint a person to act
as its alliance manager to coordinate its business activities under this Agreement, and a technical leader to coordinate its technical activities under this Agreement. Each party shall notify in writing the other party as soon as practicable upon
making, and changing, any of these appointments. The alliance managers shall be the primary business contacts, and the technical leaders shall be the primary technical contacts, between the parties with respect to their respective activities under
this Agreement. Each party shall maintain an alliance project team, with an equal number of representatives as mutually agreed upon by the parties, that consists of at least the alliance manager and technical leader. The purpose of the alliance
project team shall be to exchange information and oversee the strategic, technical and operation aspects of the alliance. The alliance project team will have monthly meetings (which will be in person at least once per quarter), unless otherwise
agreed to. Among its other responsibilities, the alliance project team shall approve the Workplan, and all amendments thereto. Notwithstanding the foregoing, but subject to Article 6, Intrexon shall have final decision-making authority with
respect to the development, manufacturing, regulatory approval and commercialization of the Product. Each party shall be responsible for its own costs in connection with the meetings of the alliance project team. Within [*****] weeks after each
meeting of the alliance project team, one party (alternating from meeting to meeting) shall prepare and provide the other party with written minutes of the discussions, decisions and action items from such meeting which shall be subject to the
reasonable approval and comment of the other party. 
 5.1.5 In addition to Section 5.1.3, Intrexon may request Halozyme
to provide authorization for regulatory agencies cross-reference appropriate regulatory filings previously made by Halozyme or its Affiliates regarding PH20 Drug which is necessary with respect to obtaining regulatory approval for any Product.
Halozyme will not unreasonably withhold letters of authorization. 
 5.2 Diligence Efforts. 

5.2.1 Intrexon shall [*****] to [*****] and following such approval, [*****] to [*****]. For purposes of this Section 5.2, [*****].

 5.2.2 Neither Intrexon nor any of its Affiliates shall develop itself, or obtain a license from or otherwise collaborate
with a third party to develop an Intrexon Subcutaneous Product. 
 5.2.3 If Intrexon permanently abandons, or permanently
ceases, development, use or commercialization of, the Product in any indication within the Licensed Field, then Intrexon shall promptly deliver written notice to Halozyme of its decision therefore, and the parties shall remove such indication from
the Licensed Field. 

  
 15 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.3 Research and Development Reports. 

5.3.1 Intrexon shall keep complete and accurate records of its activities conducted under Section 5.1.1 of this Agreement and the
results thereof. Within [*****] days after the end of each calendar year until the First Commercial Sale in the United States of a Product, Intrexon shall prepare and provide Halozyme with a reasonably detailed written report of the activities
conducted under this Agreement, and the results thereof, through such date of such report, to develop and obtain regulatory approvals to market Products. 
 5.3.2 Halozyme shall keep complete and accurate records of its activities conducted under Section 5.1.2 of this Agreement and the results thereof. Within [*****] days after the end of each calendar
year until the First Commercial Sale in the United States of a Product, Halozyme shall prepare and provide Intrexon with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such
date of such report, to develop and obtain regulatory approvals to market Products. 
 5.4 Trademarks. 

5.4.1 To the extent allowed under applicable law, Intrexon, its sublicensee or their respective Affiliates shall have the right to
determine the names and trademarks to use in connection with the promotion, marketing and sale of Products, and shall own and maintain such trademarks for use in connection with the promotion, marketing and sale of Products; provided, however, that,
to the extent legally permissible and commercially practicable, Intrexon shall include on all packaging, labeling and marketing and promotional materials regarding any Product the name HALOZYME, and the mark ENHANZE (or such other mark reasonably
requested by Halozyme) as a secondary mark, reasonably identifying that such product incorporates technology of Halozyme. The foregoing obligation shall exist so long as such marks are valid in the applicable country of sale. Nothing in this
Agreement shall create an obligation on Halozyme to register or otherwise maintain in force any marks. Halozyme shall promptly inform Intrexon, upon Intrexon’s reasonable request, as to whether the marks requested for inclusion by Halozyme are
properly registered in the applicable country of sale (with any necessary recordation or maintenance fees accounted for) and whether, to Halozyme’s knowledge, the requested marks have been determined by a governmental authority to be invalid or
unenforceable. 
 5.4.2 Except as otherwise set forth above, Intrexon, its sublicensees and their respective Affiliates shall
not (a) use any of Halozyme’s trademarks, or any mark or name confusingly similar thereto, as part of a corporate or business name or in any other manner, or (b) register any trade mark or trade name (including any company name) which
is identical to or confusingly similar to or incorporates any trade mark or trade name which Halozyme or any associated company owns or claims rights in. Any goodwill associated with any of Halozyme’s names or marks affixed or applied or used
in connection with Products shall accrue to the sole benefit of Halozyme. 

  
 16 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

	 	6.	REGULATORY MATTERS. 

 6.1
Notices. Except as otherwise set forth in this Agreement, Intrexon shall not communicate with the FDA or the governing health authorities of any country solely regarding the PH20 Drug incorporated into the Product without the prior consent of
Halozyme. If the FDA or the governing health authorities of any country initiates any oral communication with Intrexon solely regarding the PH20 Drug incorporated into the Product, Intrexon shall have the right to respond to such communication to
the extent reasonably necessary or appropriate under the circumstances; provided, however, that (a) Intrexon shall use reasonable efforts to limit the communications solely regarding the PH20 Drug incorporated into the Product that are
conducted without the participation of Halozyme; (b) promptly thereafter, Intrexon shall provide Halozyme with written notice thereof in reasonably specific detail describing the communications solely regarding the PH20 Drug incorporated into
the Product; and (c) Intrexon promptly shall provide Halozyme with copies of all minutes and other materials resulting therefrom (redacting any information that is confidential or proprietary, that does not relate to the PH20 Drug, or that it
is unable to legally disclose). Intrexon promptly shall provide Halozyme with copies of all written communications from the FDA or the governing health authorities of any country solely regarding the PH20 Drug incorporated into the Product
(redacting any information that is confidential or proprietary, that does not relate to the PH20 Drug, or that it is unable to legally disclose). With respect to any filing, communication or other submission with the FDA or the governing health
authorities of any country solely regarding the PH20 Drug incorporated into the Product, (a) Intrexon shall provide Halozyme with an advance copy of the reasonably complete draft thereof; (b) Halozyme shall have a reasonable opportunity to
review, comment and consult on such draft; (c) the parties shall discuss Halozyme’s comments solely regarding the PH20 Drug incorporated into such Product; (d) Intrexon shall in good faith consider the reasonable comments of Halozyme
solely regarding the PH20 Drug incorporated into such Product; and (e) Halozyme shall promptly respond to any inquiry from the FDA or the governing health authorities of any country that initiated communication concerning the PH20 Drug
incorporated into the Product, shall keep Intrexon reasonably informed of the subject of such communications, and shall provide Intrexon with copies of any minutes of any such proceedings to the extent such minutes relate to the Product or the
Intrexon Biologic. Halozyme shall keep Intrexon updated with respect to the regulatory strategy for the PH20 Drug incorporated into each Product and the consistency thereof with, or any differences from, Halozyme’s regulatory strategy for
Halozyme’s proprietary recombinant human PH20 hyaluronidase technology. Notwithstanding the foregoing, Intrexon shall have the sole right to communicate with the FDA or the governing health authorities of any country regarding the Intrexon
Biologic. 
 6.2 Results. Intrexon shall promptly inform Halozyme in writing, in reasonably specific detail, of any
material data, results or other information from each preclinical study or human clinical trial of a Product related to the PH20 Drug component of such Product. Halozyme shall promptly inform Intrexon in writing of any regulatory communication that
is received, or of any data, results or other information of which it becomes aware, relating to the PH20 Drug alone or as a component of a Product that may impact the safety or efficacy of a Product; provided, however, that neither party will be
required to disclose any data, results or other information (other than safety information) that will result in a breach of any confidentiality obligations with a third party. Each party acknowledges that information exchanged under this provision
may contain material, nonpublic information, a party’s awareness of which could prohibit that party from (1) buying or selling securities (stock, options, etc.) until after the information has been disclosed to the public and absorbed by
the market, and (2) passing the information on to anyone who may buy or sell securities. 

  
 17 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 6.3 Adverse Event Reporting. Each party shall promptly notify the other party of
any information that comes to such party’s attention concerning any serious or unexpected adverse event, injury, toxicity or sensitivity reaction, or any unexpected incidence, and the severity thereof, associated with the clinical uses,
studies, investigations, tests and marketing of PH20 Drug, the Intrexon Biologic or the Product. For purposes of this Section 6.3, “serious” shall mean an experience which (a) results in the death, a persistent or significant
incapacity or substantial disruption of the ability to conduct normal life functions, in-patient hospitalization or prolongation of hospitalization, or (b) is a congenital anomaly, the result of an overdose or life threatening (only if
unrelated to primary disease); and “unexpected” shall mean (x) for a nonmarketed Product, an experience that is not identified in nature, severity or frequency in the current clinical investigator’s confidential information
brochure, and (y) for a marketed product, an event which is not listed in the current labeling for such product, and includes an event that may be symptomatically and pathophysiologically related to an experience listed in the labeling but
differs from the event because of increased frequency or greater severity or specificity. Each party further shall immediately notify the other party of any information received regarding any threatened or pending action by an agency that may affect
the safety and efficacy claims of the Product. Upon receipt of any such information, the parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action; provided, however, that nothing
contained herein shall restrict either party’s right to make a timely report of such matter to any government agency or take other action that it deems to be appropriate or required by applicable law, regulation or court order. Each party shall
take all reasonable steps to protect the confidentiality of any patient health and medical information that it has access to and to comply with applicable state and federal privacy laws, as such laws apply to such party. 

 

	 	7.	SUPPLY OF API. 

 7.1
Manufacture and Sale. On the terms and conditions of this Article 7, Halozyme shall manufacture (or have manufactured), sell and deliver to Intrexon all API required by Intrexon, its sublicensees and their respective Affiliates for use
in the preclinical development, clinical development and commercialization of the Products, and Intrexon shall purchase from Halozyme all quantities of API required by Intrexon, its sublicensees and their respective Affiliates for use in the
preclinical development, clinical development and commercialization of the Products. Intrexon, its sublicensees and their respective Affiliates shall use such API supplied by Halozyme solely for the development, manufacture and commercialization of
Products pursuant to this Agreement. 
 7.2 Manufacturing Practices. 

7.2.1 Halozyme shall manufacture, or have manufactured, API under this Article 7 in conformity with the API Specifications and in
accordance with all applicable laws and regulations. The API Specifications shall not be amended without the prior written consent of both parties. Halozyme shall notify Intrexon in the event it agrees to modify the specifications for PH20 Drug
being provided to any of its other licensees. 

  
 18 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.2.2 Unless the parties otherwise mutually agree or except as otherwise contemplated
by this Agreement, Halozyme shall manufacture, or have manufactured, API under this Article 7 in accordance with cGMP as it may be in effect at the time. 
 7.2.3 Subject to Section 7.2.1, Halozyme shall [*****]. 
 7.2.4 Intrexon
shall have the right, at its sole expense, to audit Halozyme and its CMO of PH20 Drug for compliance with applicable laws and regulations and GMP on reasonable notice during normal business hours and not more than once in each calendar year, subject
to reasonable confidentiality obligations. 
 7.2.5 Halozyme shall provide Intrexon with certificates of analysis for all API
supplied hereunder based upon a reference standard established by Halozyme in accordance with all applicable rules and regulations and reasonably acceptable to Intrexon. 
 7.2.6 Upon the reasonable request of Intrexon, Halozyme shall provide Intrexon with such information, including analytical and manufacturing documentation, batch records for API and stability data, in
each case requested by Intrexon regarding quality control of API supplied under this Article 7. 
 7.2.7 All information
disclosed or obtained pursuant to this Article 7 shall be Confidential Information of Halozyme. 
 7.3 Forecasts and
Orders. 
 7.3.1 Not less than [*****] days prior to the first day of each calendar quarter (commencing with the first
calendar quarter in which Intrexon, its sublicensees or their respective Affiliates order API from Halozyme hereunder), Intrexon shall prepare and provide Halozyme with a written forecast of its good faith estimated requirements for API under this
Section 7.3 for each of the subsequent [*****] calendar quarters. Intrexon shall not (a) increase or decrease the quantity estimated for the [*****] quarterly period of each forecast from the quantity estimated for the [*****] quarterly
period of the previous forecast, (b) increase or decrease the quantity estimated for the [*****] quarterly periods of each forecast by more than [*****] percent ([*****]%) of the quantity estimated for the [*****] quarterly periods of the
previous forecast, respectively, without the prior express written consent of Halozyme. The quantities estimated for the [*****] quarterly periods of each forecast shall be non-binding, and for planning purposes only. 

7.3.2 Intrexon shall be required to purchase [*****] of the quantity forecasted for each API under this Section 7.3 for the first
and second quarterly periods of each forecast under Section 7.3.1. 
 7.3.3 Halozyme shall be required to supply the
quantity of API ordered by Intrexon under this Section 7.3 in any calendar quarter up to [*****] percent ([*****]%) of the quantity forecasted for the [*****] quarterly period of the most recent forecast. If Intrexon’s

  
 19 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
orders in any calendar quarter exceed [*****] percent ([*****]%) of the quantity forecasted for the [*****] quarterly period of the most recent forecast, Halozyme shall use commercially
reasonable efforts to supply such excess. Halozyme shall use commercially reasonable efforts to meet Intrexon’s delivery requirements specified in accordance with Section 7.3.4. In the event of a shortfall to forecast, Halozyme shall use
commercially reasonable efforts to apportion API among Intrexon and its other customers on a pro rata basis according to their respective forecasts. 
 7.3.4 Intrexon shall make all purchases under this Section 7.3 by submitting firm purchase orders to Halozyme. Each such purchase order shall be in writing in a form reasonably acceptable to
Halozyme, and shall specify the quantity of API ordered, the place of delivery and the required delivery date therefor, which shall not be less than [*****] days after the date of such purchase order. No additional terms of any such purchase order
shall be binding on Halozyme and are expressly rejected hereby. In the event of a conflict between the terms and conditions of any purchase order and this Agreement, the terms and conditions of this Agreement shall prevail. 

7.4 Delivery and Acceptance. 
 7.4.1 All API supplied under this Agreement shall be shipped [*****] (Incoterms 2010) [*****] to such location as designated by Intrexon. Any change in the location of manufacture or distribution shall
require the consent of Intrexon, such consent not to be unreasonably withheld or delayed. Title and risk of loss and damages to the API purchased by Intrexon hereunder shall pass to Intrexon upon receipt by the applicable carrier. 

7.4.2 Intrexon shall pay all [*****] applicable to the sale and transport of API purchased by Intrexon under this Section 7.3.4.

 7.4.3 If a shipment of API or any portion thereof is not in conformance with the API Specifications, then Intrexon shall
have the right to reject such shipment of API unless it is reasonably determinable that only a portion of the shipment fails to conform, in which case Intrexon shall have the right only to reject the portion thereof that fails to so conform.
Intrexon shall give written notice to Halozyme of its rejection hereunder, within [*****] days after Intrexon’s receipt of such shipment, specifying the grounds for such rejection. Notwithstanding the above, if the nonconformity of the API
could not have been ascertained by Intrexon upon reasonable inspection and analysis of the API, then the [*****] day period referred to herein shall not apply, provided that Intrexon notifies Halozyme promptly upon discovery of such nonconformity
(but in no event later than [*****] days from the date of the discovery). All or any part of any shipment may be held for Halozyme’s disposition, at Halozyme’s expense if found to be not in conformance with the API Specifications. Halozyme
shall use its commercially reasonable efforts to cure such rejection or replace such nonconforming shipment of API, or portion thereof, within [*****] days after receipt of notice of rejection thereof. 

  
 20 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.4.4 Intrexon’s grounds for rejection shall be conclusive unless Halozyme
notifies Intrexon, within [*****] days of receipt by Halozyme of the notice of rejection, that it disagrees with such grounds. In the event of such a notice by Halozyme, representative samples of the batch of API in question shall be submitted to a
mutually acceptable independent laboratory or consultant (if not a laboratory analysis issue) for analysis or review, the costs of which shall be paid by the party that is determined by the independent laboratory or consultant to have been incorrect
in its determination of whether the applicable API should be rejected. 
 7.5 [*****]. If (a) Halozyme [*****]
(b) Halozyme [*****] then Intrexon may [*****]. Within sixty (60) days after the Effective Date, Halozyme will [*****]. Notwithstanding the foregoing, (i) regardless of whether [*****], Intrexon shall [*****] [*****], Halozyme can
demonstrate to Intrexon’s reasonable satisfaction that Halozyme [*****]. 
 7.6 LIMITATION OF LIABILITY.
HALOZYME’S LIABILITY TO INTREXON, AND INTREXON’S REMEDY, UNDER SECTION 7.4.3 SHALL BE THE REJECTION AND REPLACEMENT OF NON-CONFORMING API WITH API THAT CONFORMS WITH THE TERMS AND CONDITIONS OF THIS AGREEMENT WITHIN A COMMERCIALLY
REASONABLE TIME. NOTHING IN THIS SECTION 7.6 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 10. 
 7.7 Warranty. Halozyme warrants that all API delivered to Intrexon pursuant to this Agreement shall conform with the API Specifications and the certificate of analysis, shall be free from defects
in manufacturing, handling, material and workmanship, and shall be manufactured in accordance with cGMP as in effect at the time (unless the parties otherwise mutually agree) and in compliance with applicable laws and regulations. EXCEPT AS

  
 21 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, HALOZYME MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO API. HALOZYME DISCLAIMS ALL OTHER WARRANTIES, EXPRESS AND IMPLIED,
INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. NOTHING IN THIS SECTION 7.7 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY
UNDER ARTICLE 10. 
 7.8 Supply Strategy. Commencing not later than the [*****] anniversary of the Effective Date,
Halozyme shall be responsible for implementing a commercially reasonable supply strategy for API to meet Intrexon’s reasonably anticipated forecasts provided pursuant to Section 7.3. Halozyme shall review such supply strategy with Intrexon
at least [*****], and prior to implementing any material change required by a CBE-30, a Prior Approval Supplement or equivalent regulatory filing. Halozyme shall notify Intrexon of any annual reportable changes within [*****] days after their
submission to FDA. 
 7.9 Quality Agreement. The parties agree to negotiate and enter into a mutually acceptable quality
agreement relating to the supply of API hereunder. Such quality agreement shall be entered into within [*****] days of the Effective Date. 
 7.10 Supply of API After Expiration of this Agreement. During the [*****] month period before the anticipated expiration of this Agreement, and upon the written request of Intrexon, the
parties shall negotiate in good faith the terms and conditions regarding the continued supply of API by Halozyme to Intrexon. 
  

	 	8.	INTELLECTUAL PROPERTY RIGHTS. 

 8.1 Ownership of Intellectual Property. The intellectual property rights and ownership outlined in this Article 8 shall supersede the intellectual property rights and ownership terms of the
Material Transfer Agreement dated May 23, 2011 between Halozyme and Intrexon. Each party shall assist the other party in any reasonable manner to obtain, perfect and enforce the other party’s rights in any and all countries, in and to all
intellectual property as set forth below. In addition, the Parties agree to assign, or cause to be assigned, intellectual property rights in and to all intellectual property as set forth below. The Parties agree that: 

8.1.1 Intrexon shall solely own the Collaboration Supported Intrexon Biologic Patents and any unpatentable Collaboration Inventions
solely relating to the Intrexon Biologic; 
 8.1.2 Halozyme shall solely own the Collaboration Supported PH20 Patents and any
unpatentable Collaboration Inventions solely relating to the PH20 Drug; and 
 8.1.3 Intrexon and Halozyme shall jointly own
the Collaboration Supported Product Patents and any Collaboration Invention that is not a Collaboration Supported Intrexon Biologic Patent or Collaboration Supported PH20 Patent, or if unpatentable does not solely relate to the Intrexon Biologic or
does not solely relate to the PH20 Drug. 

  
 22 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 8.2 Prosecution, Maintenance and Enforcement. 

8.2.1 Intrexon shall have the first right, at its sole expense, to prepare, file, prosecute and maintain the Collaboration Supported
Product Patents. Intrexon shall give Halozyme an opportunity to review and comment on the text of each patent application included within the Collaboration Supported Product Patents before filing, shall supply Halozyme with a copy of such patent
application as filed, together with notice of its filing date and serial number, and shall give Halozyme an opportunity to review and comment on the text of all correspondence received from any patent office. Intrexon shall consider in good faith
the interests of Halozyme in the prosecution of the Collaboration Supported Product Patents. Halozyme shall assist Intrexon, upon request and at Intrexon’s sole expense, and to the extent commercially reasonable, in connection therewith. If
Intrexon elects not to file any patent application included in the Collaboration Supported Product Patents in any country, or decides to abandon any such pending application or issued patent in any country, then Intrexon shall provide written notice
to Halozyme, and Halozyme shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent at its own expense. 

8.2.2 Intrexon shall have the first right to enforce the Collaboration Supported Product Patents against third party infringers. With
respect to any infringement of the Collaboration Supported Product Patents by a third party, if Intrexon fails to abate such infringement or to file an action to abate such infringement within ninety (90) days after a written request from
Halozyme to do so, or if Intrexon discontinues the prosecution of any such action after filing without abating such infringement, then Halozyme shall have the right to enforce the Collaboration Supported Product Patents against such third party
infringer. With respect any action to enforce the Collaboration Supported Product Patents to abate any infringement by a third party, all monies recovered upon the final judgment or settlement of any such action shall (a) first, be used to
reimburse the costs and expenses (including reasonable attorneys’ fees and costs) of Halozyme and Intrexon; and (b) second, (i) if Intrexon brings such enforcement action, be treated as Net Sales, except for recovered punitive damages
which are to be shared equally between the parties and (ii) if Halozyme brings such enforcement action, be shared equally between the parties. 
 8.2.3 Intrexon shall have the sole right, at its sole expense, to prepare, file, prosecute, maintain and enforce the Collaboration Supported Intrexon Biologic Patents. Intrexon shall consider in good
faith the interests of Halozyme in so doing. Halozyme shall assist Intrexon, upon request and at Intrexon’s sole expense, and to the extent commercially reasonable, in connection therewith. Nothing in this Agreement grants any ownership right
in the Collaboration Supported Intrexon Biologic Patents to Halozyme, and Intrexon shall remain the sole owner of the Collaboration Supported Intrexon Biologic Patents. 
 8.2.4 Halozyme shall have the sole right, at its sole expense, to prepare, file, prosecute, maintain and enforce the Collaboration Supported PH20 Patents and Licensed Patent Rights. Halozyme shall
consider in good faith the interests of Intrexon in so doing. Intrexon shall assist Halozyme, upon request and at Halozyme’s sole expense, and to the extent commercially reasonable, in connection therewith. Nothing in this Agreement grants any
ownership right in the Collaboration Supported PH20 Patents or the Licensed Patent Rights to Intrexon, and Halozyme shall remain the sole owner of the Collaboration Supported PH20 Patents and the Licensed Patent Rights. 

  
 23 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 8.2.5 With respect to any substantial and continuing infringement of the Licensed
Patent Rights by a third party making, using, offering for sale, selling or importing a product that consists of an Exclusive Biologic combined with PH20 Drug
 ([*****]) that is directed to the Exclusive Field in a country, on a
country-by-country basis, if Halozyme fails to abate such infringement or to file an action to abate such infringement within [*****] days (or [*****] days in the case of a paragraph IV certification) after a written request from Intrexon
to do so, or if Halozyme discontinues the prosecution of any such action after filing without abating such infringement, then until such time as such infringement is abated, the royalty rate for the Product in such country shall be reduced by
[*****] of the royalty rate set forth in Section 4.4. 
 8.2.6 With respect any action to enforce the Licensed Patent
Rights to abate any infringement of the Licensed Patent Rights by a third party making, using, offering for sale, selling or importing a product that consists of an Exclusive Biologic combined with PH20 Drug ([*****]) that is directed to the
Exclusive Field in a country, all monies recovered upon the final judgment or settlement of any such action shall be used (a) first, to reimburse the costs and expenses (including reasonable attorneys’ fees and costs) of Halozyme and
Intrexon; and (b) the remainder to be shared equally between the parties. 
 8.3 Grantback License. Intrexon hereby
grants to Halozyme a perpetual, royalty-free, fully paid up, nonexclusive, worldwide license under any Grantback Patents for the purpose of developing, making, using, selling, offering for sale or importing PH20 Drug ([*****]) alone or combined with
any biologic or molecule, in each case other than (i) Products in the Licensed Field, or (ii) products that consist of an Exclusive Biologic combined with PH20 Drug ([*****]) that is directed to the Exclusive Field. Halozyme shall have the
right to grant sublicenses under such rights to any third party provided that such third party has similarly granted to Halozyme a grantback license (with the right to sublicense to Intrexon). If Halozyme is unable to obtain such a grantback license
from any such third party, then Halozyme shall not grant a sublicense to such third party under the foregoing license grant from Intrexon, and any such sublicense granted by Halozyme to such third party shall be void. For the avoidance of doubt, the
foregoing license grant shall not include rights to any molecule separate from the combination with PH20 Drug ([*****]). 
  

	 	9.	CONFIDENTIALITY. 

 9.1
Confidentiality. During the term of this Agreement and for a period of [*****] following the later of (i) the expiration or earlier termination hereof or (ii) the last commercial sale of a product developed hereunder, each party
shall maintain in confidence the Confidential Information of the other party, shall not use or grant the use of the Confidential Information of the other party except as expressly permitted hereby, and shall not disclose the Confidential Information
of the other party except on a need-to-know basis to such party’s affiliates, directors, officers, employees and consultants, to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement and provided that the recipient of the Confidential Information is subject to an 

  
 24 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
existing written agreement to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other party except as expressly permitted under this Agreement. Each
party shall notify the other party promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information. Notwithstanding the foregoing, with respect to any Confidential Information that the disclosing
party deems to be a “trade secret” under applicable law, the confidentiality obligations hereunder shall continue with respect to such Confidential Information for so long as it is deemed a trade secret under applicable law. 

9.2 Terms of Agreement. Neither party shall disclose any terms or conditions of this Agreement to any third party without the
prior consent of the other party; provided, however, that a party may disclose the terms or conditions of this Agreement (a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary or
(b) to a third party in connection with (i) an equity investment in such party, (ii) a merger, consolidation or similar transaction by such party, (iii) the sale of all or substantially all of the assets of such party or
(iv) a collaboration or strategic alliance relating to the subject matter of this Agreement. 
 9.3 Permitted
Disclosures. The confidentiality obligations under this Article 9 shall not apply to the extent that a party is required to disclose information by applicable law, regulation, stock exchange listing or order of a governmental agency or a
court of competent jurisdiction; provided, however, that (to the extent practicable) such party shall provide written notice thereof to the other party, consult with the other party with respect to such disclosure and provide the other party
sufficient opportunity to object to any such disclosure or to request confidential treatment thereof. 
 9.4
Publications. Either party may publish the results of its research and/or development under this Agreement in order to obtain recognition within the scientific community and to advance the state of scientific knowledge, and such publication
shall be subject to the following procedures. If a party desires to make any such publication (including any oral disclosure made without obligation of confidentiality), such party shall provide the other party with a copy of the proposed written
publication at least thirty [*****] prior to submission for publication, or an outline of such oral disclosure at least [*****] days prior to presentation. At the request of the other party, the publishing party shall remove any Confidential
Information of the other party therefrom. The other party additionally shall have the right (a) to propose modifications to the publication for patent reasons, and (b) to request a reasonable delay in publication in order to protect
patentable information. If the other party requests such a delay, the publishing party shall delay submission or presentation of the publication and shall not proceed with the written publication or the presentation without the prior written consent
of the other party, such consent not to be unreasonably withheld (provided that it would be unreasonable (x) for Intrexon to withhold consent if Intrexon’s primary reason for doing do is marketing concerns due to the Product performing
better than a Intrexon Subcutaneous Product or (y) for Halozyme to withhold consent if Halozyme’s primary reason for doing so is marketing concerns due to the Product performing worse than a Intrexon Subcutaneous Product). 

9.5 Clinical Trial Registry. Intrexon, in accordance with ClinicalTrials.gov or equivalent regulatory agency policies and
procedures, shall have the right to publish all studies, clinical trials and results thereof regarding Product (but not PH20 Drug alone) on the clinical trial registries which are maintained by or on behalf of Intrexon. 

  
 25 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

	 	10.	INDEMNIFICATION AND INSURANCE. 

 10.1 By Intrexon. Intrexon shall indemnify and hold harmless Halozyme, its Affiliates and their respective directors, officers, employees and agents, from and against all losses, liabilities,
damages and expenses, including reasonable attorneys’ fees and costs (collectively, “Liabilities”), resulting from any claims, demands, actions or other proceedings by any third party to the extent resulting from (a) the
breach of any representation, warranty or covenant by Intrexon under this Agreement; (b) the use by Intrexon, its sublicensees or their respective Affiliates of the Licensed IP Rights beyond the scope of the licenses granted herein;
(c) the manufacture, use, sale, handling or storage of Products by Intrexon, its sublicensees or their respective Affiliates, customers or end-users; or (d) the use by Intrexon, its sublicensees or their respective Affiliates of the
Confidential Information of Halozyme; provided, however, that the foregoing indemnification obligation shall not apply to the extent the applicable Liability results from clauses (a) – (d) under Section 10.2 below. 

10.2 By Halozyme. Halozyme shall indemnify and hold harmless Intrexon, its Affiliates and their directors, officers, employees and
agents, from and against all Liabilities resulting from any claims, demands, actions or other proceedings by any third party to the extent resulting from (a) the breach of any representation, warranty or covenant by Halozyme under this
Agreement; (b) the use by Halozyme, its sublicensees or their respective Affiliates of the Grantback Patents beyond the scope of the licenses granted herein; (c) the manufacture, use, sale, handling or storage of API by Halozyme or its
CMOs or other suppliers; or (d) the use by Halozyme, its sublicensees or their respective Affiliates of the Confidential Information of Intrexon; provided, however, that the foregoing indemnification obligation shall not apply to the extent the
applicable Liability results from clauses (a) – (d) under Section 10.1 above. 
 10.3 Procedure. If a
party (the “Indemnitee”) intends to claim indemnification under this Section 10.3, it shall promptly notify the other party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for
which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to the parties;
provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due
to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceeding. The obligations of this Section 10.3 shall not apply to amounts paid in settlement of any claim, demand,
action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the
commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Section 10.3. The Indemnitee, its employees and agents, shall reasonably cooperate
with the Indemnitor and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Section 10.3. 

  
 26 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 10.4 Insurance. Each party shall maintain insurance, including Commercial General
Liability, Product and Clinical Trials Liability, Workers Compensation and Employer’s Liability and Errors and Omissions Liability insurance, with respect to its activities under this Agreement regarding Products in such amount as such party
customarily maintains with respect to similar activities for its other products, but not less than the greater of (i) $[*****] each occurrence and aggregate for Commercial General Liability, Product and Clinical Trials Liability and Errors and
Omissions Liability insurance and $[*****] limit per accident /disease and a $[*****] disease policy limit Workers Compensation and Employer’s Liability or (ii) such amount as is reasonable and customary in the industry. Each party shall
maintain such insurance for so long as it continues its activities under this Agreement, and thereafter for [*****] years. Each party retains the right to insure or self-insure at its sole discretion, the above coverage. Each party shall
provide the other party [*****] days notice of any material change, cancellation or non-renewal of any required insurance under this Agreement. In the event of a material change, cancellation, or non-renewal in coverage, each party shall
replace such coverage to comply with this Agreement so that there is no lapse of coverage for any time period. 
  

	 	11.	TERM AND TERMINATION. 

11.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to this Article 11,
shall continue in effect until the later of (a) expiration of the last to expire of the Valid Claims, and (b) expiration of the last to expire Royalty Term. Upon the expiration (but not termination) of this Agreement, Intrexon shall have a
perpetual, fully paid-up, non-exclusive license under the Licensed Know-How Rights to make, have made, use, sell, offer for sale and import Products for use in the Licensed Field. 

11.2 Termination for Breach. If a party has materially breached this Agreement and such material breach shall continue for [*****]
days after written notice of such breach was provided to the breaching party by the nonbreaching party, the nonbreaching party shall have the right at its option to terminate this Agreement effective at the end of such [*****] day period.

 11.3 Termination by Intrexon. Intrexon may terminate this Agreement in whole or on a Product-by-Product basis at any
time upon [*****] days prior written notice to Halozyme. 
 11.4 Effect of Expiration or Termination. 

11.4.1 Expiration or termination of this Agreement shall be without prejudice to any rights which shall have accrued to the benefit of a
party prior to such expiration or termination. Without limiting the foregoing, Sections 2.3, 4.7, 6, 7.6, 8, 9, 10, 11.4 and 12 shall survive any expiration or termination of this Agreement. 

11.4.2 Except as otherwise expressly set forth in this Agreement, promptly upon the expiration or earlier termination of this Agreement,
each party shall return to the other party all tangible items regarding the Confidential Information of the other party and all copies thereof; provided, however, that each party shall have the right to retain one (1) copy for its legal files
for the sole purpose of determining its obligations hereunder. 

  
 27 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 11.5 Section 365(n) of the Bankruptcy Code. All rights and licenses
granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under section 365(n) of the Bankruptcy Code. 

 

	 	12.	MISCELLANEOUS. 

 12.1
Governing Law. This Agreement shall be governed by, interpreted and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law principles thereof. 

12.2 Waiver. No waiver by a party hereto of any breach or default of any of the covenants or agreements herein set forth shall be
deemed a waiver as to any subsequent and/or similar breach or default. 
 12.3 Assignment. Neither this Agreement nor any
right or obligation hereunder may be assigned or delegated, in whole or part, by either party without the prior express written consent of the other; provided, however, that either party may, without the written consent of the other, assign this
Agreement and its rights and delegate its obligations hereunder to an Affiliate, or in connection with the transfer or sale of all or substantially all of its business related to this Agreement, or in the event of its merger, consolidation, change
in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 12.3 shall be void. 

12.4 Independent Contractors. The relationship of the parties hereto is that of independent contractors. The parties hereto are
not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. 
 12.5 Further Actions. Each party shall execute, acknowledge and deliver such further documents and instruments and to perform all such other acts as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement. 
 12.6 Notices. All requests and notices required or permitted to
be given to the parties hereto shall be given in writing, shall expressly reference the section(s) of this Agreement to which they pertain, and shall be delivered to the other party, effective on receipt, at the appropriate address as set forth
below or to such other addresses as may be designated in writing by the parties from time to time during the term of this Agreement. 
  

			
	If to Halozyme:	    	Halozyme, Inc.
		    	11388 Sorrento Valley Road
		    	San Diego, California 92121
		    	Attn: Chief Executive Officer

  
 28 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

			
	If to Intrexon:	    	Intrexon Corporation
		    	20358 Seneca Meadows Pkwy
		    	Germantown, Maryland 20876
		    	Attn: Legal Department

 12.7 Force Majeure. Nonperformance of a party (other than for the payment of money) shall be
excused to the extent that performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and
not caused by the negligence, intentional conduct or misconduct of the nonperforming party; provided, however, that the nonperforming party shall use commercially reasonable efforts to resume performance as soon as reasonably practicable.

 12.8 No Consequential Damages. IN NO EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL
DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS
SECTION 12.8 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 10. 
 12.9 Halozyme In-Licenses. Notwithstanding anything to the contrary in this Agreement, the grant of rights by Halozyme under this Agreement shall be subject to and limited in all respects by the
terms of the applicable Halozyme In-Licenses pursuant to which Halozyme acquired any Licensed IP Rights, and all rights or sublicenses granted under this Agreement shall be limited to the extent that Halozyme may grant such rights and sublicenses
under such Halozyme In-Licenses, in each case to the extent specifically identified on Schedule 1.26. Halozyme shall keep the Halozyme In-Licenses in full force and effect throughout the term of this Agreement. 

12.10 Complete Agreement. This Agreement, together with the Schedules hereto, constitutes the entire agreement between the parties
regarding the subject matter hereof, and all prior representations, understandings and agreements regarding the subject matter hereof, either written or oral, expressed or implied, are superseded and shall be and of no effect. 

12.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and together
shall be deemed to be one and the same agreement. 
 12.12 Headings. The captions to the several sections hereof are not
a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. 

  
 29 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by
their duly-authorized representatives as of the Effective Date. 
  

			
	HALOZYME, INC.
		
	By:	 	 /s/ Gregory I. Frost

		
	Name:	 	 Gregory I. Frost

		
	Title:	 	 President & CEO

	
	INTREXON CORPORATION
		
	By:	 	 /s/ Gerardo Zapata

		
	Name:	 	 Gerardo Zapata

		
	Title:	 	 President Protein Production and SVP

  
 30 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.3 
 API Specifications 
 [*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.26 
 Halozyme In-Licenses 
 CONFIDENTIAL 

[*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.28 
 Intrexon Biologic 
 [*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 2.2.1(a) 

Licensed Patent Rights 
 [*****] 

  
 34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]